


PROVEN INNOVATION ENHANCE EFFICIENCY  
PROVEN INNOVATION INCREASE SAFETY ENHANCE EFFICIENCY IMPROVE CARE  
IMPROVE CARE QUALITY WITH PROVEN  
INNOVATION INCREASE SAFETY ENHANCE EFFICIENCY IMPROVE CARE QUALITY INCREASE SAFETY IMPROVE  
WITH PROVEN INNOVATION INCREASE SAFETY ENHANCE EFFICIENCY IMPROVE CARE QUALITY INCREASE SAFETY IMPROVE  
INCREASE SAFETY ENHANCE EFFICIENCY IMPROVE CARE QUALITY INCREASE SAFETY IMPROVE CARE QUALITY  
WITH PROVEN INNOVATION INCREASE SAFETY ENHANCE EFFICIENCY IMPROVE CARE QUALITY INCREASE SAFETY IMPROVE  
ENHANCE EFFICIENCY IMPROVE CARE QUALITY INCREASE SAFETY ENHANCE EFFICIENCY IMPROVE  
PROVEN INNOVATION INCREASE SAFETY ENHANCE EFFICIENCY IMPROVE CARE QUALITY INCREASE SAFETY  
INCREASE SAFETY ENHANCE EFFICIENCY IMPROVE CARE QUALITY INCREASE SAFETY ENHANCE EFFICIENCY IMPROVE  
IMPROVE CARE QUALITY  
INCREASE SAFETY

CERNER:  
WE MAKE HEALTHCARE  
SMARTER.





# A LETTER TO OUR SHAREHOLDERS, CLIENTS AND ASSOCIATES

March 31, 2000

As predicted, 1999 was an unpredictable year. Cerner made great operational progress but our financial performance was disappointing.

## Summary Highlights for 1999

- **Financial Results:** Cerner's financial results were disappointing with revenues of \$340 million, up less than 3%; gross margin of \$245 million, up less than 2%; and net earnings, before non-recurring charges, down 71% to \$6.9 million.
- **Significant Operational Success:** Healthcare providers were using over 530 HNA Millennium® applications at the end of 1999; approximately 50% of these were converted in the last six months of the year. Our tremendous success in converting HNA Millennium applications demonstrates the strength of our architecture, the quality of our applications and the maturity of our products. It also demonstrates that, as we emerge from the massive technology build stage for HNA Millennium, the five-year investment cycle is beginning to yield dramatic benefits.
- **The Balanced Budget Act:** This legislation took its full grip on healthcare providers in the United States during 1999, significantly reducing the operating margins of hospitals and physician groups while raising their cost of capital. This hostile economic environment, along with our client's preoccupation with Y2K projects, significantly impacted our ability to grow our revenues in 1999.
- **eHealth was Born:** Although eHealth is still being defined, it was born with great promise during the year. Cerner is at the center of this creation with our significant ownership position in and strategic relationship with CareInsite. A merger between CareInsite and Healthon/WebMD was announced on February 14, 2000. We believe that this pending transaction will amplify Cerner's role as a major participant in eHealth.
- **The Healthcare Information Technology (HCIT) Competitive Landscape:** Since the beginning of 1999, the HCIT industry landscape has changed significantly. Two major competitors were acquired, or agreed to be acquired, while a third is being actively pursued. In this evolving environment, Cerner focused its resources on investing in products and services which truly create value for our clients. We believe this focus has improved our competitive position, allowing us to more effectively address the tremendous opportunities in the healthcare marketplace.
- **Institute of Medicine (IOM) Articulation of the Tragedy of Medical Errors:** The IOM released a report called "To Err is Human" on November 29, 1999, indicating that medical error is one of the top ten causes of death in the United States. A significant majority of these deaths are preventable with Cerner information technology – today!
- **Y2K Arrived Slowly, with Much Fanfare, and Quickly Was Forgotten:** At midnight, December 31, 1999, the two-digit date field in many legacy computer applications rolled from "99" to "00". As we assisted our clients in their preparation for this technology event, Cerner completed almost 1,000 extra projects during 1999, most of which were not reimbursable. Our clients spent billions of dollars preparing for Y2K, an expenditure that generated little incremental value toward improving their capabilities to lower cost, improve quality or make healthcare delivery safer. The good news is that Y2K is now history.
- **Cerner Stock Price:** Recently, Cerner's stock price hit an all-time high and is now trading at \$27, which is up 100% over its price in November 1999.

## The 1990's: A Decade of Progress and Results

This is Cerner's last Annual Report for the 1990s. A decade is a meaningful period of time for which to review our progress.

During the 1990s several core strategies defined our company. Over the next ten years these strategies will continue to define Cerner and, we believe, our industry. In an environment that is constantly changing, with enormous opportunities emerging from within as well as from without, we believe the consistency of these core strategies creates tremendous strength, stability and leverage for Cerner today and well into the new millennium.

### **Leadership Through Vision**

The healthcare delivery industry is a very inefficient, sometimes unsafe, industry that produces a result with a high degree of variance in quality. This is a harsh statement for an industry that is committed to enhancing and preserving the quality of life. Significant advancements and development have come from the marvels of the science and technology of medicine and the number of truly caring, brilliant people who have given their lives to delivering healthcare. However, the organizational delivery models of healthcare have not benefited from the same level of innovation. We believe the industry needs a vision on how to transform itself and that information technology will be the key source of leverage healthcare executives will use in this transformation. Cerner has made a major contribution to help shape the industry's vision over the past ten years. We are recognized for it. It is this vision, which guides Cerner.

### **Common Information Architecture for Healthcare Delivery**

The healthcare delivery system is highly fragmented. Cerner has a long-held belief that information technology can serve as *the* foundation for the delivery of healthcare across these disparate organizational boundaries. We have executed on this belief by investing over \$200 million in building the industry's most comprehensive, contemporary information architecture – Health Network Architecture™ (HNA), the Millennium version. HNA Millennium creates solutions for healthcare delivery organizations across the entire continuum of care. It goes deep into the workflows of the many clinical, operational and business services of healthcare delivery. It is extensible into managed care, disease management and demand management organizations. Our architecture is designed around the person, creating an information platform that enables health services to be accessible anytime, anywhere. It is this unique, person-focused design principle that has positioned HNA Millennium to be the backbone of the new emerging eHealth community.

### **Mission Critical Applications First**

Cerner has always believed huge value can be created by first focusing on the mission of an industry rather than the administration of the industry. That has led us to become the leading clinical information systems company in the world. Today almost 80% of every dollar spent in healthcare is spent because a physician makes a clinical decision. In the near future, given the explosion of internet connectivity, Cerner technology will be instrumental in redefining how physicians and consumers interact to make these decisions, empowering and informing the consumer in the redefined process. While the administration of healthcare is very costly and cumbersome and needs to be redesigned, this redesign must start with the clinical process. Cerner has done exactly that, attacking the clinical mission first and then following with the administration. Cerner will be delivering to healthcare organizations, in 2000, a next generation set of business applications designed from that perspective.

### **Organic Growth**

We have witnessed significant consolidation in the healthcare information technology industry. Many of our competitors have used acquisition-based business plans to create short-term growth, which endears them to Wall Street for a period of time. Cerner has always questioned whether 'fundamental value' can be created for our clients by amassing pre-existing, disparate information technologies. Cerner's core growth strategy has been to create value by developing great software within industrial strength architecture. The overall results produced by this strategy were tremendous over the decade of the 90s. Over a 10-year period, Cerner revenues grew nearly 600% with a 10-year Compound Annual Growth Rate (CAGR) of 21%; Gross margins grew over 1000% with a 27% 10-year CAGR and shareholders experienced a 1200% increase in share value based on the end-of-the-year price of \$19.69 or over a 1600% increase based on more recent share prices. We are, by most measures today, considered the third largest healthcare information technology company in the world and we are the clearly the largest clinical information systems company delivering mission critical applications to healthcare. Although we clearly under-performed in creating incremental shareholder value during the last half of the 1990s, we believe strongly that we have created a position that is an outstanding starting point for the next decade.

## In the Short-term: Our Year 2000 Plan

In the last paragraph of last year's 1998 Annual Report Letter, we said that 1999 would be very unpredictable. It was. And it's over. While we do expect healthcare delivery organizations to continue to be under financial pressure for the next two to three years, we believe the year 2000 is much more predictable. Y2K is gone and forgotten and the realities of BBA are now clearly understood by our clients. Healthcare providers can now focus on building better delivery systems. We have built our year 2000 plan based on these expected realities. We are focused on achieving four goals: revenue growth, operating margin expansion, growing our presence in eHealth and operational excellence.

*Revenue Growth:* The completion and maturing of HNA Millennium gives us an excellent opportunity to take market share from our competitors by offering the industry a state-of-the-art architecture and significantly expanding the number of solutions we offer healthcare providers. We are investing in growing the size of our direct sales force, having already doubled its size in the last six months of 1999. We are also focused on growing significant market opportunities outside the United States.

*Operating Margin Expansion:* We believe we can grow our bottom line by expanding our operating margins in our Client Services and our Cerner Consulting groups while at the same time decreasing the relative investment we make in engineering, as a percent of our revenues, now that the major build of HNA Millennium is complete.

*Presence in eHealth:* As we said, our technology investment in HNA Millennium was designed around the person. In the age of the connected and empowered consumer this looks very smart. Now, we see eHealth opportunities everywhere we look. In 1998 and 1999 we leveraged our investment in HNA Millennium into significant value for Cerner's shareholders through our CareInsite (and now, potentially, Healtheon|WebMD) relationship. We also have enormous opportunities to work with our clients to define their role in the new age eHealth space. Year 2000 is a critical period for developing this wave of new opportunities.

*Operational Excellence:* A significant portion of our thinking and plan for the year 2000 is simply to become much better at what we do. That includes continuing to build great software and world-class architecture, delivering great professional and technical services to our clients, helping our clients achieve their visions while realizing a return on their investments with Cerner, and providing great post-installation service for our solutions. To be a great company, we must have great talent and great execution.

*Cerner executive management and associates are committed to delivering all four goals.*

## Over the Long-term: Opportunities for the New Decade

We believe the opportunities for Cerner over the next ten years are enormous. We are in the world's largest industry (healthcare is over 14% of the United States economy) and we are the world's best-positioned company to help transform this industry with information technology. Currently, healthcare organizations are seeing increased workflow volume while the reimbursement per case decreases. We believe that the healthcare industry will reach an inflection point within the next decade, creating the emergence of 'New Health Enterprises' using information technology as the 'digital backbone'.

The 'New Health Enterprise' will require information systems that can manage care delivery virtually across an entire community while simultaneously managing the business services side of healthcare management. This will require managing care from the 'living room' to the 'operating room' in a paperless, smart fashion. In this digital environment, Cerner envisions that consumers and physicians will be able to choose from a variety of electronic access devices (e.g., personal computers, network computers, entertainment/internet portals, Personal Digital Assistants and home/personal-based diagnostic and therapeutic technology) to connect directly to the clinical processes of care and for accessing a complete health record for each individual. This precise and specific personal medical information will be used to create a customized health system for each person in the community as well as establishing large data repositories storing and tracking health outcomes over many lives and multiple lifetimes. New knowledge and medical insights will be gained from the use of this trusted data. New, powerful 'transaction engines' that securely manage healthcare transactions from each point of access to their destination will redefine the basic workflows of healthcare. These 'transaction engines' will allow preferencing and customization by the consumer and physicians. They will embed clinical rules, clinical evidence and protocols to monitor care safety and quality. Finally, they will use business and compliance rules to create more efficient business management between the health enterprise and their payors, patients, community, supply chain, physician groups, and outside business relationships.

We plan to become the dominant company innovating, designing and building the information technology for health-care in this new environment. We expect our HNA Millennium architecture to become the backbone for eHealth, redefining the healthcare transactions and connections for consumers, doctors, payors, and employers as well as participants in the supply chains. We will be able to create a new set of professional and technology services for our clients utilizing the new delivery platforms we are building. We believe there are enormous opportunities for Cerner in the emerging data and knowledge discovery marketplace.

In short, Cerner has the opportunity to transform healthcare. And in doing so, we will create significant value for our shareholders, clients, and associates.

As with everything in business there are few guarantees. We do, however, believe we have the vision, experience, energy and resources to achieve great things early in this new decade. The year 2000 will be a great launching point.


Very truly yours,



Neal L. Patterson  
Chairman and Chief Executive Officer



Clifford W. Illig  
Vice Chairman



Earl H. Devanny, III  
President



Glenn P. Tobin, Ph.D.  
Executive Vice President &  
Chief Operating Officer

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 10-K

(Mark One)

**ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the fiscal year ended January 1, 2000

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [NO FEE REQUIRED]**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number 0-15386

**CERNER CORPORATION**

(Exact name of Registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation or organization)

43-1196944

(I.R.S. Employer Identification Number)

2800 Rockcreek Parkway  
Kansas City, Missouri 64117  
(816) 221-1024

(Address of principal executive offices, including zip code;  
Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: NONE

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, par value \$.01 per share  
Preferred Stock Purchase Rights  
(Title of Class)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

At March 15, 2000, there were 33,794,735 shares of Common Stock outstanding, of which 7,810,343 shares were owned by affiliates. The aggregate market value of the outstanding Common Stock of the Registrant held by non-affiliates, based on the average of bid and asked prices of such stock on March 15, 2000, was \$772,223,643.

Documents incorporated by reference: portions of the Registrant's Proxy Statement for the 2000 Annual Meeting of Stockholders are incorporated by reference in Part III hereof.

## **PART I**

### **Item 1. Business**

#### **Overview**

Cerner Corporation (“Cerner” or the “Company”) is a Delaware corporation incorporated in 1980. The Company’s principal offices are located at 2800 Rockcreek Parkway, Kansas City, Missouri 64117, and its telephone number is (816) 221-1024.

Cerner designs, develops, markets, installs and supports information technology and content solutions for healthcare organizations and consumers that are capable of being implemented on an individual, combined or enterprise-wide basis and are accessible over the internet by consumers, physicians and healthcare providers. Cerner’s integrated suite of solutions enable healthcare providers to improve operating effectiveness, reduce costs and improve the quality of care as measured by clinical outcomes. Cerner’s solutions are designed to provide the appropriate health information and knowledge to care givers, clinicians and consumers and the appropriate management information to healthcare administration on a real-time basis, allowing secure access to data by clinical and administrative users in organized settings of care and by consumers from their home. These solutions can be implemented as part of an enterprise-wide solution or individually, leveraging the client’s existing investment in information technology. Cerner solutions are available as integrated applications managed by our clients or as a service option under the Applications Solutions Provider (ASP) model, where applications are provided to clients from Cerner’s solutions center in Kansas City, Missouri. Cerner solutions are designed and developed using the Health Network Architecture (“HNA”), a single information architecture. HNA is a unified technology infrastructure for combining clinical and management information applications. HNA allows each participating healthcare organization to access an individual’s clinical record at the point of care, to organize it for the specific needs of the physician, nurse, laboratory technician or other care provider on a real-time basis, and to use the information in management decisions to improve the efficiency and productivity of the entire enterprise. HNA solutions allow healthcare organizations to reduce costs of delivering care, reduce clinical variance, reduce medical errors, and improve patient safety. Cerner has developed and is licensing and installing or offering as a service, its newest generation of HNA solutions known as “Millennium”. See “Cerner’s Technology - Health Network Architecture (HNA) and HNA Millennium” for a discussion of HNA Millennium.

#### **Healthcare Industry**

While the rate of healthcare cost increases has slowed in the last five years, the demand for healthcare services has continued unabated. A more health conscious and better-informed health consumer combined with the aging of the population in general has accelerated the demand for healthcare services. In most markets the drive toward pure capitation (a fixed monthly fee per member in payment for all required services) and a primary care gatekeeper model as key components of managed care has slowed. A virtual integrated health organization built upon connections, partnerships, alliances, and relationships with physician, payors, employers, and suppliers is emerging as the operating model for health organizations. In order to operate effectively in this virtual model, healthcare organizations must increasingly rely on broadly deployed information technology to accomplish the integration necessary to manage costs and deliver high quality patient outcomes.

The healthcare delivery industry in the United States is highly fragmented, very complex and remarkably inefficient. While science and medical technology continue to make significant breakthrough progress in dealing with human disease and injury, the management and clinical processes of these complex delivery organizations have made little progress in the past twenty years. Even today, the major clinical workflow depends on manual, paper-based medical record systems augmented by spotty automation. This has resulted in an industry which is economically inefficient and produces significant variances in medical outcomes. In November 1999, the Institute of Medicine released a report called “To Err is Human” indicating that medical error is one of the top ten causes of death in the United States. The industry must address these issues by identifying ways to enhance efficiencies and improve the quality of care.

The healthcare industry has also been buffeted by significant external forces during the 1990’s. Managed Care Organizations defined themselves as an intermediary in the flow of funds and exerted pressures on healthcare spending. These pressures resulted in lowering total spending on healthcare but did not necessarily address any of the larger, systemic issues in the industry. As a result of the pressures created by managed care, healthcare providers consolidated both horizontally and vertically into newly defined delivery systems. It is clear many of these delivery systems were created to form entities to negotiate with managed care but many organizations also expected new economies of scale. For the most part these economies never materialized.

A number of for-profit business models were created during the decade attempting to find the leverage point which would transform the healthcare delivery system. The models included for-profit acute care, physician practice management companies and, most recently, the carve-out focused factories specializing in one element of healthcare, such as cardiology. Most of these efforts have been unsuccessful.

Finally, Federal government policy in the United States has also been an active force shaping the health care environment. The policy impact includes the focus on health care reform in the 1992 presidential election, the very aggressive Medicare Fraud and Abuse compliance programs initiated during the decade and, most recently, the passing of the Balanced Budget Act, which reduced payments to health care providers by over \$250 billion dollars over a five-year period. This legislation took its full grip on providers here in the United States during 1999, significantly reducing the operating margins of hospitals and physician groups while raising their cost of capital.



In order to be competitive in this dynamic marketplace, healthcare enterprises will need to deploy information technology solutions that internally automate the paper-based medical record systems and externally create smart connections between the major participants in health care: the consumer, the physician, the hospital and the managed care organization. The emergence of near ubiquitous internet connectivity has enabled a new class of eHealth solutions that allow the consumer to participate fully in the care and health management process. This same technology has also enabled a new way to deliver these solutions under the Application Services Provider (ASP) model, whereby information solutions are delivered to clients from a remote location.

The complexity of healthcare's information requirements will continue to increase with provider consolidations and the challenging cost containment pressures created by the Balance Budget Act. The soon to be published final regulations under the Health Insurance Portability and Accountability Act of 1996 add an additional element of uncertainty for healthcare organizations around security and patient confidentiality. Physician organizations are affected by the same pressures and will increasingly need to utilize person/patient focused information systems (i) to improve quality and efficiency for their growing practices and physician networks, (ii) to develop the data necessary to compete for contracts with payors and (iii) to be able to share the financial risks of healthcare delivery. Managed care organizations are increasingly recognizing the value of process-oriented and clinically driven information to understand and improve the health of their members, to reduce medical errors and to reduce costs. These larger, more complex integrated healthcare enterprises are seeking closer relationships with technology suppliers that can provide comprehensive information systems solutions, including integrated process-based systems for clinical domains, data repositories, applications for physicians and management teams and consumer connectivity.

Cerner is responding to the changing and increasing needs of the healthcare industry for better information systems by developing HNA Millennium, its latest generation of solutions. See "Cerner's Technology - Health Network Architecture (HNA) and HNA Millennium" for a discussion of HNA Millennium.

### **Healthcare Information Technology (HCIT) Industry**

The Healthcare Information Technology industry is evolving to meet the needs of a changing marketplace. Beginning in the 1960's, computer systems developed for use in healthcare were financially oriented, with a focus on the ability to capture charges and generate patient bills and update the general ledger. Later, hospital and commercial organizations began to use clinical information systems, which automate the activities within clinical departments, such as laboratory, pharmacy, radiology and surgery departments, to improve the productivity of resources and automate the production and use of significant amounts of clinical information. During the late eighties and early nineties, individual clinical departments selected systems based upon specific features on a "best of breed" basis resulting in disparate and disconnected information systems within the institution.

Most recently, there has been a shift from the purchase of disparate clinical systems selected on a "best of breed" basis to systems that are able to integrate communication effectively throughout the healthcare enterprise. This approach requires a common system architecture, in which system's functional components are engineered and built with a common data model, messaging system, standards and other lower level technical components. The system users enjoy a common look and feel as well as common navigation capabilities. This infrastructure trend also affects the relationship between the health system and the suppliers of information technology. Moving to a common architecture approach requires the creation of a strategic relationship with one HCIT company dedicated to implementing a shared vision for the role of information in the operation of the health system.

Many HCIT companies have responded to this trend by acquiring smaller HCIT companies with existing application offerings and thereby offering a "solution" under one brand to the market place. Attempts to integrate these disparate architectures have not delivered the anticipated clinical or financial benefits for clients or HCIT companies. In the long run, the Company believes that value for consumers and providers will center on a common architectural framework that allows the seamless transmission of knowledge and processes among all the healthcare constituents.

The internet's role in the transformation of healthcare is not well defined at present, but all indications are that it will be one of the major enablers of the shift to a consumer-centric industry. As more and more households have internet access, consumers have access to an increasing amount of health information, resulting in an informed and empowered healthcare consumer.

The same infrastructure that is automating the clinical and managerial operations of the medical center and clinic is extending to all trading partners within the healthcare industry. Managed care authorizations, referrals, claims and remittance can be submitted to local, regional, and national exchanges for rapid processing. Orders for tests and results can be securely transmitted over the internet to physicians and consumers alike. Most importantly, consumers will have the option of working closely with their local healthcare organization to organize and manage their care or selectively work with providers on an as needed basis. An internet-based personal health record will emerge to assist patients and caregivers with maintaining the wide variety of health and care related information.

Cerner's HNA Millennium solutions, with their person-centric design and web-based architecture, are well suited to meet the requirements of the connected health system. See "Cerner's Technology - Health Network Architecture (HNA) and HNA Millennium" for a discussion of HNA Millennium.

## The Cerner Vision

Cerner's vision is to enable the transformation of healthcare through the implementation of information technology and the deployment of medical knowledge. As a result of the rapid changes in the healthcare and information technology industries, Cerner believes that a "New Health Enterprise" will emerge with a digital center and an information "backbone" which connects consumers, physicians, hospitals, pharmacies, home health agencies and payors to service the healthcare needs of a community or defined member population. This digital information backbone is enabled by the increased connectivity created by the internet.

Cerner believes that healthcare delivery systems will reach an inflection point within the next decade, creating the emergence of these New Health Enterprises in the United States. Currently, healthcare organizations are seeing increased workflow volume while the reimbursement per case decreases. The New Health Enterprise will require information systems that can manage care delivery virtually across an entire community while simultaneously managing the business services side of healthcare management. This will require managing care from the person/patient's home to the Intensive Care Unit in a paperless fashion. In this digital environment, Cerner envisions that consumers and physicians will be able to choose from a variety of electronic access devices (e.g. Personal Computers linked to internet portals, Personal Digital Assistants, home/personal-based diagnostic and therapeutic technology) to connect to the clinical process of care and create or review a complete health record for each individual. This precise and specific personal medical information will create large data repositories storing and tracking health outcomes over multiple lifetimes. New knowledge and medical insights will be harvested from this data. Cerner's products securely manage health care transactions from each point of access to their destination. Cerner's products also allow preferencing and customization to the consumer and physicians, embed business rules, clinical evidence and protocols to monitor care safety and quality, and use of business and compliance rules to create more efficient business management between the health enterprise and their payors, patients, physician groups, supply chain, community, and outside business relationships.

## Cerner's Technology — Health Network Architecture (HNA) and HNA Millennium

The cornerstone of Cerner's technology strategy is HNA, the single architecture around which each of Cerner's information products is developed. This open, highly scalable architecture allows Cerner to meet the clinical, management, and business information requirements of a healthcare delivery system across the continuum of care. Cerner's newest version of HNA computing platform, Millennium, developed between 1994 and 1999, utilizes N-tiered client/server technology to optimize distributed computing performance and scalability across multiple client and server platforms. The HNA Millennium architecture and applications were designed and developed to accommodate healthcare specific requirements for mission critical computing and secure access, whether the user is inside the healthcare enterprise or at home via the internet. HNA Millennium's breadth of focus and functionality are well suited for large-scale and enterprise application technologies for healthcare organizations, including the ability to leverage the internet for eHealth-related self-service and business to business functions.

The value of HNA Millennium to a client organization is the use across a healthcare organization of a single system based on a fully integrated common architecture and database. With its single data model, HNA Millennium provides real time access to all information across multiple applications, domains, organizations and physical locations, including physician, hospital, nursing, laboratory, pharmacy, and consumers, to all of those needing such access, wherever they are located. Given its integrated and open design, HNA Millennium can also provide a centralized repository of clinical and financial transactions to help standardize access and messaging of disparate applications across a health system.

The alternative to an architectural approach is to use disparate systems based on differing architectures and data structures to automate the care processes across the continuum of care. These disparate systems must be interfaced together and rely on these interfaces to transmit, modify and arrange data exchanged between them, which limits the data's usefulness across multiple systems and inhibits real-time access. In addition, many of these systems lack functional scalability and cannot operate across multiple provider settings or locations within a healthcare organization.

Two overarching capabilities are embedded into the HNA Millennium architecture: (i) person centric transactions and messaging, which considers the breadth of requirements not only of a patient, but also of healthy consumers, and (ii) healthcare community dynamics, which takes into account the flexibility required by the constantly changing relationships between healthcare organizations, physicians and consumers, and the need to maintain complex security and end user preferences based on the context and business attributes of the transaction in a community setting.

## Strategy

Key elements of the Company's business strategy include:

*To penetrate the integrated healthcare provider market.* The transformation of healthcare delivery must deal with the changing financial model from fee-for-service to fixed or controlled fee payments for services provided. In order to accomplish the transition, integrated healthcare systems must decrease costs generally, utilize fewer resources per patient or member encounter, decrease the amount of care required by focusing on preventative measures and increase member populations by attracting additional members through better quality healthcare and services. Cerner's process-based, clinical and management systems provide the technology to enable an integrated system to manage healthcare to significantly reduce costs, improve the efficiency of healthcare delivery and maintain and improve the quality of healthcare.

*To expand its market share in individual domains.* Cerner expects continued growth in clinical domain systems for specific markets such as nursing, physician office, laboratory, pharmacy, radiology, surgery, emergency medicine and cardiology, as institutional providers look to restructure and reengineer these high cost centers. The Company also intends to market aggressively Cerner clinical and management information systems and services to its existing client base.

*To remain committed to a common architecture.* Because Cerner believes that the constituents in health management need to work together to benefit defined populations in a community, the Company has made a commitment to a single unified architecture as the platform for “fully integrated” health information and management systems. This platform enables Cerner’s process-based HNA systems to be scaleable on a linear basis, using either Cerner compatible modules for process-oriented applications or competitive systems interfaced using open system protocols.

*To expand its products and services.* Using HNA Millennium, Cerner intends to continue expanding the range of products and services offered to providers either through internal development or by acquisitions or joint ventures. These new products and services will complement the systems currently offered, address the emerging information needs of clients or employ technological advances. Cerner believes that major opportunities exist as providers and managed care organizations reach into new markets and offer more alternative services to remain competitive. The Company believes these organizations will find value in having personal health records and trusted health information accessible to the individual in the home. In addition, Cerner recognizes the value of the aggregate database being developed by its broad client base as a potential means to enable comparative or normative procedure evaluations as a powerful new tool in the healthcare industry. The substantial project management process redesign, technology integration, and training involved in healthcare systems taking advantage of the opportunities provided by clinical and management information technology represent a significant market for the Company’s consulting services.

*To offer web-based solutions.* The Company has extended its product offerings around the HNA Millennium architecture to facilitate powerful business-to-consumer and business-to-business connections via the internet. This satisfies healthcare consumers’ increasing demands for anytime, anywhere access to health information, communication with their physician, access to services and management of a personal health record. Cerner’s expertise in complex clinical and management information systems allows health organizations to create and brand a health “portal” in their community that connects consumers, physicians, hospitals, disease management providers, payors, reference labs, pharmacies, and supply-chain organizations via the internet. Bringing the consumer and provider closer together in the context of the health record creates an opportunity for the majority of Cerner’s products to deploy via the internet. Cerner currently has applications that are developed and being used for web deployment. Cerner also provides content and applications to other internet-focused companies, and in the future will offer additional internet services and solutions, as the business demand requires.

*To offer its products as an Application Service Provider.* The Company now offers its HNA Millennium applications through its new Application Service Provider (ASP) organization. The ASP organization offers information technology services to clients in a package that includes software, computer hardware, implementation, technical support, wide-area network (WAN) services and automatic software upgrades. Unlike traditional software implementations, software delivered through an ASP is not installed at the user’s location, but is delivered, operated, and maintained in Cerner’s solutions center in a rapidly accelerated implementation timeframe with a smaller initial user investment. Using Cerner’s ASP, any size organization can access the same robust clinical applications, architecture, and user-interface advantages that were previously only available to larger institutions.

## **Our Technology – Information Product Suites**

The Company’s technology includes Enterprise Systems, which automate processes across and throughout the health system enterprise; Enterprise Repositories, which capture, sort, present and analyze clinical and business information; Clinical Systems for Direct Care, which automate the clinical processes within hospitals and the physicians practice; Clinical Systems for Care Centers, which automate the clinical processes within specific departments or domains; Decision Support Systems and Knowledge Solutions, which enhance clinical and business processes with information and actions; Financial and Operational Management Systems, which automate the business operations; Population Health Management systems for managing health; Demand Management systems and services for managing the need for care; Personal Health systems for individuals to manage their own health; and Interface Technologies for connecting other technologies to HNA Millennium. These systems can be acquired individually or as a fully integrated health information system. The individual systems perform together even if installed at different times. Cerner’s applications can all be delivered over the internet in a web browser using third-party application server software or for selected applications, native web implementations. Cerner also markets over 200 product options that complement Cerner’s major information systems. In connection with the licensing of an information system, Cerner also generally sells to its client’s computers, related hardware, networks and sub-licensed software components that are manufactured and supplied to Cerner by third parties.

## Enterprise Systems and Enterprise Repositories

Cerner's Enterprise Systems automate processes across the entire health system. *Capstone* automates the identification, eligibility, registration and scheduling processes across hospitals, clinics, physician practices and other care delivery organizations, integrating the health system and incorporating existing systems. It includes a structured repository for the storage and viewing of health plan information, records, contracts, eligibility and coverage data. *PowerLink* connects community-based physicians to health systems for referrals, authorizations, claims, eligibility, and reporting. *PowerChart* is the enterprise clinician's desktop solution for viewing, ordering and documenting the electronic medical record, which is maintained in the *Open Clinical Foundation (OCF) data repository*. *ePowerChart* extends the power of this viewer to the web. Physicians can gain access to the electronic medical record to view results and documentation from any internet-based terminal. It includes a structured repository for the storage of person/patient orders; discrete results; clinical reports and other documents; indexes to document images from foreign document imaging systems; and indexes to third-party dictation systems.

*Open Management Foundation (OMF) Data Repository* is a structured repository for process- and activity-related information useful for management of a healthcare organization. Information can originate from numerous sources and can be maintained in an easily accessible, standardized format. OMF can be integrated into an architecture containing products from different suppliers.

## Clinical Systems for Direct Care

*Cerner's CareNet Acute Care Management System* is designed to automate the entire care process in acute or institutional settings. It collects, refines, organizes, and evaluates detailed clinical and management data. It enables the entire care team to plan and manage individual activities and plans, as well as measure outcomes and goals. *CareNet* consists of two major solutions – *Care Team Automation*, which automates documentation related to care delivery at the point of care within an acute care organization, including nursing order entry and viewing of the patient's medical record, as well as basic registration capabilities; and *Care Coordination*, which supports acute care planning, including pathways used to audit care, nursing care plans, multidisciplinary care plans, single-discipline pathways and multidisciplinary pathways.

The *INet Intensive Care Management System* is designed to automate the entire care process in intensive care settings. It supports chart review and browsing, order management, documentation management, and automatic data acquisition, as well as basic patient management. It automatically acquires patient data from bedside medical devices, manages information flow and presentation at the bedside, supports care management through care planning and critical pathways, and encourages timely decisions based on comprehensive data availability; information tailored to the practitioner and the patient; and rule-based decision support.

The *ProVide Physician Office Management System* supports the broad range of clinical and business activities that occur within a physician office, clinic, or large physician organization (such as a multi-site clinic or management service organization) and ties the office together with others in the community. It automates key activities of the care team in both primary and specialty care settings. *ProVide* offers clinicians and staff a variety of functional capabilities, including patient/member tracking, clinical records access and navigation, eligibility checking, order and referral processing, and reference library access and navigation. *ProVide* allows an enterprise to deliver a common medical record effectively integrating the ambulatory and acute care record in one single instance. In addition to the traditional implementation and operations model, this system is immediately deployable under an ASP model hosted in Cerner's solutions center and includes options for the rapid implementation of the solution.

The *ProCall Home Care Management System* automates the clinical and business processes of home health organizations, such as visiting nurse associations and hospices. It is appropriate for Medicare-certified or noncertified agencies providing skilled nursing, specialized care, supervisory activities, assessments, and unskilled attendant or medical delivery services. *ProCall* facilitates the documentation of care activities in the home and provides access to the electronic medical record. It automates the referral, scheduling, and management reporting processes performed by office personnel in home care agencies, and supports their business and administrative processes. In addition to these solutions, *ProCall* also supports telephonic documentation to allow patients and caregivers to document activities and results by using a touch-tone phone. Financial and management reporting capabilities provide needed information to directors and managers in home care agencies to allow them to compete in a prospective-pay environment. Interfaces to patient billing systems are also supported. The *ProCall* system is immediately deployable under an ASP model hosted in Cerner's solutions center and includes options for the rapid implementation of the solution.

## Clinical Systems for Care Centers

The *PathNet Laboratory Information System* addresses the information management needs of six clinical areas: general laboratory, microbiology, blood bank transfusion services, blood bank donor services, anatomic pathology, and human leukocyte antigen. *PathNet* automates the ordering and reporting of procedures, the production of accurate and timely reports, and the maintenance of accessible clinical records. The *PathNet* system is immediately deployable under an ASP model hosted in Cerner's solutions center and includes options for the rapid implementation of the solution. To facilitate electronic ordering by community physicians and to allow the rapid dissemination of lab results, Cerner also provides *PathNet*, a web-based application for both order and results. *PathLink* combines the order critiquing, routing and labeling logic of *PathNet* with the convenience of the web.

The *RadNet Radiology Information System* addresses the operational and management requirements of diagnostic radiology departments or services. It allows a department to replace its manual, paper-based system of record keeping with an efficient computer-based system. Specific modules on mammography, film tracking, and inventory management are also offered. Incorporated in the *RadNet* system is the capability to display and route medical images in a viewer called *ProView*. Complex interfaces to major PACS (Pictorial Archive Retrieval Systems) are also offered to integrate the radiology information system to the PACS.

The *PharmNet Pharmacy Information System* provides full integration in an HNA environment for rapid pharmacy order entry and support of the clinical pharmacy in either an inpatient or outpatient/retail setting. PharmNet streamlines medication order entry, enabling the pharmacist or technician to place all types of pharmaceutical orders on one easy-to-use screen. Dispensing functions, including interfaces to automated dispensing devices also are fully supported. Medication fill lists, intravenous fill lists and medication administration records are produced automatically or on demand.

The *SurgiNet Surgery Information System* is designed to address the needs of the surgical department, including automating the functions of resource and equipment scheduling, inventory management, anesthesia management and operating room management. Case cart management, preference cards, and peri-operative documentation are key attributes of the system.

The *FirstNet Emergency Medicine Information System* offers patient and provider tracking and an intuitive presentation of patient diagnoses and clinical events for the emergency department. *FirstNet* provides basic emergency department functionality, including quick admits, tracking, triage, and patient history, as well as a graphical reference to patient location and order status. Physician documentation following structured documentation pathways is also offered.

The *CVNet Cardiology Information System* automates the processes within the department of cardiology, supporting the scheduling, ordering, documentation and data capture required by professionals in the cardiology domain.

#### Decision Support Systems and Knowledge Solutions

*Discern Expert* is an event-driven, rule-based, decision support software application that allows users to define clinical and management rules that are applied to events accessing data that is captured or generated by other HNA applications. It supports both synchronous (real-time, interactive) processing and asynchronous (noninteractive) processing of events. *Discern Expert* manages the evaluation and display of executable clinical knowledge through both Cerner-developed Alerts and *Insights*, which are licensed separately, or client-developed alerts.

*Discern Explorer* is a decision support software application integrated with other Cerner HNA clinical and management information systems that allows users to execute predetermined or ad hoc queries and reports regarding process-related data that is generated by the other HNA applications.

*Alerts* and *Insights* are automated clinical guidelines that, through Cerner systems, provide decision support. *Alerts* represent specific, synchronous (interactive) or asynchronous (noninteractive), rule-based alerts that operate in conjunction with *Discern Expert*. *Insights* are specific, synchronous (interactive), rule-based clinical guidelines that operate in conjunction with *Discern Expert* and that are peer-reviewed and medically researched.

*Care Designs* are clinical pathways and protocols that automate the specific plans of care for an individual, and operate within Cerner's clinical systems.

*Health Facts* is Cerner's comparative data warehouse for benchmarking information and services for subscribers to support their own improvement processes. Data is provided from client's information systems as well as national and regional data sets. The Health Facts warehouse is hosted at Cerner's World Headquarters and accessed via the web by any web browser.

#### Financial and Operational Management Systems

The *ProFit Enterprise Billing & Accounts Receivable System* is Cerner's system for revenue accounting, billing and accounts receivables for the entire health system as well as each individual domain or organization.

The *ProRate Agreement Management System* is a system designed to automate the managed care processes around membership, eligibility tracking, claims processing and contract management.

The *ProLogue Enterprise Management System* includes a suite of management applications specifically designed to assemble and use the information contained in the *Open Management Foundation* to help an organization complete its strategic plans, including clinical metrics, case profiling, and performance profiling of individuals and organizations.

The *ProFile Health Information Management System* helps meet the operations management needs of the health information management (medical records) department and includes functionality for the various chart tracking and completion tasks commonly associated with maintaining medical records.

The *ProCure Materials Management System* and the *ProTrack Equipment Management System* automate the business operations around supply chain and includes materials and equipment management for the organization.

#### Population Health Management

*Survey and Assessments* produces personal health risk assessments and analyzes those to create interventions that promote self-care and improve health. The offering includes both (i) the tools necessary to build unique survey instruments to assess patient wellness, functional status and satisfaction and (ii) specific content to score a health risk assessment.

#### Demand Management

*Health Connections* is a demand management system that includes applications and services to automate and manage the operations of a call center, including protocol-based triage, referral management and person information. The *ProLink Call Center Management System* is Cerner's suite of applications that enables call centers to automate the telecare function for providers as well as health plans or disease management companies.

#### Personal Health

*Vitality* is Cerner's internet-based home software product designed to extend medical care to the consumer's home. It provides a way for the consumer to interact on a regular basis with a healthcare provider. *Vitality* can store health and medical records for easy access. By providing health appraisals and personalized health plans, *Vitality* takes the first step toward improving health education for members in a community. *Vitality* can be tightly integrated into the person record within the health system or can stand alone. In either case, relevant health information can be shared among providers and the patient under control of the patient. *Vitality* can be hosted at the client data center or at Cerner's solution center.

#### Interface Technologies

The *Open Engine Application Gateway System* facilitates the exchange of data and assists in the management of point-to-point interfaces between foreign systems. It serves as a toolkit to help write interface code. The *Open Port Interface System* represents Cerner's standardized technology for providing reliable foreign system, medical device, and other standard interfaces in a timely manner. Message translation and data mapping are done with point-and-click tools and a scripting environment. Communications protocols are configured via table-driven parameters. These sophisticated methodologies result in decreased implementation times and greater client satisfaction.

#### **Software Development**

Cerner commits significant resources to developing new health information system products. As of January 1, 2000, 1,022 employees were engaged full-time in product development activities. Total expenditures for the development and enhancement of the Company's products were approximately \$88,699,000, \$74,159,000 and \$54,524,000 during the 1999, 1998 and 1997 fiscal years respectively. These figures include both capitalized and noncapitalized portions and exclude amounts amortized for financial reporting purposes.

The Company expects to continue investment and development efforts for its current and future product offerings. As new clinical and management information needs emerge, Cerner intends to enhance its current product lines with new versions released to clients on a periodic basis. In addition, Cerner plans to expand its current product lines by developing additional information systems for clinical, financial, operational and/or consumer use and to continue to support simultaneous use of Cerner's products across multiple facilities. All Cerner systems are developed under HNA using a proprietary systems development methodology. This methodology defines and controls each task throughout the product development cycle and ensures that current and future products can be fully integrated.

The Company is committed to maintaining open attributes in its system architecture through operability in a diverse set of technical and application environments. The Company strives to design its systems to co-exist with disparate applications developed and supported by other suppliers. This effort is exemplified by Cerner's Open Engine and OMF product lines.

See "Cerner's Technology - Health Network Architecture (HNA) and HNA Millennium" for a discussion of the development of Cerner's latest generation of software products.

#### **Sales and Marketing**

The markets for Cerner's information system products include integrated delivery networks, physician groups and networks and their management service organizations, managed care organizations, hospitals, medical centers, free-standing reference laboratories, blood banks, imaging centers, pharmacies, pharmaceutical manufacturers, employer coalitions, and public health organizations. To date, a substantial portion of system sales have been in clinical applications in hospital-based provider organizations. Cerner's HNA architecture is highly scaleable, with applications being used in hospitals ranging from under 50 beds to over 2,000 beds and managed care settings with over 2,000,000 members. All Cerner systems are designed to operate on computers manufactured by Compaq Computer Corporation ("Compaq"). In addition, many Cerner Classic

applications are available on IBM's RISC System/6000 AIX (UNIX) platform. All HNA Millennium applications are designed to operate on either Compaq or IBM platforms, thereby allowing Cerner to be price competitive across the full range of size and organizational structure of healthcare providers. The sale of a health information system usually takes approximately nine to eighteen months, from the time of initial contact to the signing of a contract.

The Company is in the process of expanding its sales force in anticipation of increased market demands expected to be created by its HNA Millennium solutions. See "Cerner's Technology - Health Network Architecture (HNA) and HNA Millennium" for a discussion of the development of Cerner's latest generation of software products.

The Company's executive marketing management is located in its Kansas City, Missouri, headquarters, while its account representatives are deployed across the United States. The Company, through subsidiaries and joint ventures, has sales staff and/or offices in Australia, Canada, Singapore and Saudi Arabia. The Company has a nonexclusive distribution agreement with Siemens Health Service GmbH & Co. KG by which its products are marketed, implemented and supported in Europe and elsewhere. Cerner's consolidated revenues include foreign sales of \$24,001,000, \$17,545,000 and \$16,272,000 for the 1999, 1998 and 1997 fiscal years, respectively. The Company supports its sales force with technical personnel who perform demonstrations of Cerner's products and assist clients in determining the proper hardware and software configurations. The Company's primary direct marketing strategy is to generate sales contacts from its existing client base and through presentations at industry seminars and tradeshows. Cerner attends a number of major tradeshows each year and has begun to sponsor executive conferences, which feature industry experts who address the information system needs of large healthcare organizations.

At the end of 1998 Cerner licensed HNA Millennium functionality to CareInsite, Inc. ("CareInsite"), in exchange for a 19.9% equity interest in such company. Cerner currently has a 18.7% equity interest in CareInsite. CareInsite is majority owned by Medical Manager, Inc. ("Medical Manager") and was formed for the purpose of creating internet-based physician connectivity and electronic commerce. In February of 2000, CareInsite and Medical Manager announced an agreement to merge with Healtheon/WebMD Corporation. The merger is subject to shareholder approval and regulatory clearance.

### **Client Services**

All of Cerner's clients enter into software maintenance agreements with Cerner for support of their Cerner systems. In addition to immediate software support in the event of problems, these agreements allow these clients the use of new releases of the Cerner products covered by these agreements. Each client has 24-hour access to the client support staff located at Cerner's corporate headquarters. Most of Cerner's clients also enter into hardware maintenance agreements with Cerner. These arrangements normally provide for a fixed monthly fee for specified services. In the majority of cases, Cerner subcontracts hardware maintenance to the hardware manufacturer.

Cerner recently modified its strategy of using regional business centers to provide support for its clients. Due to the increase in the number of Cerner personnel working at client sites and the resulting decrease in utilization and cost effectiveness of its regional branch offices, Cerner decided to close its facilities in Atlanta, Boston, Dallas, Los Angeles and Washington, D.C. effective April 30, 2000. Cerner's offices in Detroit and Denver will remain open.

### **Backlog**

At January 1, 2000, Cerner had contract backlog of approximately \$338,614,000. Such backlog represents system sales from signed contracts, which had not yet been recognized as revenue. The Company recognizes revenue on a percent of completion basis, based on certain milestone conditions, for its software products. At January 1, 2000, the Company had approximately \$75,360,000 of contracts receivable, which represents revenues recognized under the percent of completion method but not yet billable under the terms of the contract. At January 1, 2000, Cerner had a software support and maintenance backlog of approximately \$162,798,000. Such backlog represents contracted software support and hardware maintenance services for a period of twelve months. The Company estimates that approximately 47% of the aggregate backlog of \$501,412,000 will be recognized as revenue during 2000.

### **Other Factors Affecting the Company's Business**

Information under the caption "Factors that may Affect Future Results of Operations, Financial Condition or Business" included in "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Item 7 is incorporated herein by reference. Such information includes a discussion of various factors that could, among other things, affect the Company's business in the future, including (i) variations in the Company's quarterly operating results; (ii) volatility of the Company's stock price; (iii) market risk of investments; (iv) changes in the healthcare industry; (v) significant competition; (vi) the Company's proprietary technology may be subjected to infringement claims or may be infringed upon; (vii) possible regulation of the Company's software by the U.S. Food and Drug Administration or other government regulation; (viii) the possibility of product-related liabilities; (ix) possible failures or defects in the performance of the Company's software; (x) the possibility that the Company's anti-takeover defenses could delay or prevent an acquisition of the Company; and (xi) risks and uncertainties related to the Year 2000 transition.

## Item 2. Properties

The Company's offices are located in a Company-owned office park in North Kansas City, Missouri, containing approximately 500,000 square feet of useable space. As of January 1, 2000, the Company was using approximately 436,000 square feet and substantially all of the remainder was leased to tenants. The Company also leases office space for its branch offices in Detroit, Denver and Australia. The Company's current leases for office space in Boston and Washington, D.C. terminate at the end of April. The Company is negotiating the termination of or planning to sublease its current leases for office space in Atlanta, Dallas and Los Angeles.

## Item 3. Legal Proceedings

On June 11, 1999, a lawsuit was filed against the Company and eleven other companies engaged in various aspects of the healthcare information systems business. The lawsuit was brought in the United States District Court for the Northern District of Texas Fort Worth Division and is entitled Allcare Health Management System, Inc. v. Cerner Corporation, et al., and sought damages for patent infringement. The case was dismissed with prejudice with respect to the Company on February 9, 2000 and the Company entered into an agreement with Allcare and its principals to obtain a license to use the patent which was the subject of the litigation, as well as all future patents of Allcare and all patents related to healthcare information systems of Allcare's principals issued prior to February 1, 2012.

## Item 4. Submission of Matters to a Vote of Security Holders

No matters were submitted to a vote of the stockholders of the Company during the fourth quarter of the fiscal year ended January 1, 2000.

### Item 4A. Executive Officers of the Company

The following table sets forth the names, ages, positions and certain other information regarding the Company's executive officers as of March 27, 2000. Officers are elected annually and serve at the discretion of the board of directors.

<u>Name</u>	<u>Age</u>	<u>Positions</u>
Neal L. Patterson	50	Chairman of the Board of Directors and Chief Executive Officer
Clifford W. Illig	49	Vice Chairman of the Board of Directors
Earl H. Devanny, III	48	President
Glenn P. Tobin, Ph.D.	38	Executive Vice President and Chief Operating Officer
Jack A. Newman, Jr.	52	Executive Vice President
Paul M. Black	41	Senior Vice President and Chief Sales Officer
Alan D. Dietrich	37	Senior Vice President
Stephen M. Goodrich	48	Senior Vice President
Douglas M. Krebs	42	Senior Vice President and President of Cerner International
Thomas C. Tinstman, M.D.	54	Senior Vice President and Chief Medical Officer
Marc G. Naughton	45	Vice President and Chief Financial Officer
Stanley M. Sword	38	Vice President and Chief People Officer
Jeffrey A. Townsend	36	Vice President and Chief Engineering Officer
Randy D. Sims	39	Vice President, Chief Legal Officer and Secretary
Richard J. Flanigan, Jr.	40	Vice President and General Manager
Stephen D. Garver	39	Vice President and Managing Partner
Paul J. Sinclair	42	Vice President, Senior Partner and North American Operations Officer

Neal L. Patterson has been Chairman of the Board of Directors and Chief Executive Officer of the Company for more than five years. Mr. Patterson also served as President of the Company from March of 1999 until August of 1999.

Clifford W. Illig has been a Director of the Company for more than five years. He also served as Chief Operating Officer of the Company for more than five years until October, 1998 and as President of the Company for more than five years until March of 1999. Mr. Illig was appointed Vice Chairman of the Board of Directors in March of 1999.

Earl H. Devanny, III joined the Company in August of 1999 as President. Prior to joining the Company, Mr. Devanny served as president of the Health Care Information Systems Division of ADAC Laboratories. Prior to joining ADAC, Mr. Devanny served as a Vice President of Cerner from 1994 to 1997. Prior to that he spent seventeen years with IBM Corporation.

Glenn P. Tobin, Ph.D. joined the Company in April of 1998 as General Manager and Senior Vice President. On October 29, 1998, Dr. Tobin was appointed Executive Vice President and Chief Operating Officer. Prior to joining the Company, Dr. Tobin served as a senior consultant with McKinsey and Co., Inc. for more than five years.



Jack A. Newman, Jr. joined the Company in January 1996 as Executive Vice President. Prior to joining the Company, he was with KPMG LLP for twenty-two years. Immediately prior to joining Cerner he was National Partner-in-Charge of KPMG's Health Care Strategy Practice.

Paul M. Black joined the Company in March, 1994 as a Regional Vice President. He was promoted in December 1998 to his current position. Prior to joining Cerner, he spent twelve years with IBM Corporation.

Alan D. Dietrich joined the Company in 1990 as Director of Business, Planning and Development. In January 1994 he was promoted to Senior Vice President.

Stephen M. Goodrich joined the Company in October 1987 as a project leader in the product organization. In 1992 he was promoted to Vice President and was promoted to Senior Vice President in April 1999.

Douglas M. Krebs joined the Company in June 1994 as Regional Vice President. He was promoted to Senior Vice President and Area Manager in April 1999. On February 1, 2000, Doug was appointed as President of Cerner International, Inc., a wholly owned subsidiary of the Company. Prior to joining Cerner, he spent fifteen years with IBM Corporation.

Thomas C. Tinstman, M.D. joined the Company in November 1995 as Senior Vice President and Chief Medical Officer and has been a Director of the Company since May 1989. Prior to joining the Company, Dr. Tinstman was Director of Medical Informatics with University of Texas Medical Branch in Galveston, Texas. Prior to that he was a physician in private practice with Internal Medicine Associates, P.C. in Omaha, Nebraska.

Marc G. Naughton joined the Company in November 1992 as Manager of Taxes. In November 1995 he was named Chief Financial Officer and in February 1996 he was promoted to Vice President.

Stanley M. Sword joined the Company in August 1998 in his current role. Prior to joining Cerner, he served as a client partner in the outsourcing practice of AT&T Solutions for more than five years.

Jeffrey A. Townsend joined the Company in June 1985. Since that time he has held several positions in the product organization and was promoted to Vice President in February 1997. He was appointed Chief Engineering Officer in March 1998.

Randy D. Sims joined the Company in March 1997 as Vice President and Chief Legal Officer. Prior to joining the Company, Mr. Sims worked at Farmland Industries, Inc. for three years where he served most recently as Associate General Counsel. Prior to Farmland, Mr. Sims was in-house legal counsel at The Marley Company (now a division of United Dominion Industries) for seven years. Mr. Sims started his career at Marley as an attorney and was Assistant General Counsel when he left to join Farmland.

Richard J. Flanigan Jr. joined the Company in November 1994 as Regional Vice President. In 1997, his responsibilities were extended and he was named as General Manager. Prior to joining Cerner, Mr. Flanigan spent more than thirteen years in sales and management positions at IBM Corporation.

Stephen D. Garver joined the Company in March 1992 as part of Cerner Consulting. In March of 1999 he was named Vice President and Managing Partner. Prior to joining the Company, Mr. Garver spent ten years with Andersen Consulting in a variety of roles within the systems integration practice.

Paul J. Sinclair joined the Company in October 1996 as Vice President and Area Operations Officer. In March of 1999 he was named Senior Partner and North American Operations Officer. Prior to joining the Company, he worked for seven years at Seer Technologies.

## PART II

### Item 5. Market for the Registrant's Common Stock and Related Security Holder Matters

The Company's common stock trades on The Nasdaq Stock Market<sup>SM</sup> under the symbol CERN. The following table sets forth the high, low, and last sales prices for the fiscal quarters of 1999 and 1998 as reported by The Nasdaq National Market System. These quotations represent prices between dealers and do not include retail mark-up, mark-down, or commissions, and do not necessarily represent actual transactions.

	1999			1998		
	High	Low	Last	High	Low	Last
First quarter	27 1/4	12 7/8	15 5/8	24 9/16	19 1/16	21 15/16
Second quarter	23 1/2	12 1/2	19 33/64	29 15/16	20 7/8	27 7/8
Third quarter	19 15/16	14 1/4	14 31/32	31 7/16	22	22 5/8
Fourth quarter	20 3/4	12 15/16	19 11/16	27 1/16	20 1/2	26 3/4

At February 14, 2000, there were approximately 1,300 owners of record. To date, the Company has paid no dividends and it does not intend to pay dividends in the foreseeable future. Management believes it is in the stockholders' best interest to reinvest funds in the operation of the business.

### Item 6. Selected Financial Data

	1999 (1) (2)	1998(3)	1997	1996	1995
<b>(In thousands, except per share data)</b>					
Statements of Earnings Data:					
Revenues	\$ 340,197	330,902	245,057	189,107	186,901
Operating earnings	3,698	33,530	22,170	10,601	37,265
Earnings before income taxes and extraordinary item	302	33,268	24,484	12,902	37,220
Extraordinary item – early extinguishment of debt	(1,395)	-	-	-	-
Net earnings (loss)	(1,211)	20,589	15,148	8,251	22,521
Earnings per share before extraordinary item:					
Basic	.01	.63	.46	.25	.75
Diluted	.01	.61	.45	.25	.72
Earnings (loss) per share:					
Basic	(.04)	.63	.46	.25	.75
Diluted	(.04)	.61	.45	.25	.72
Weighted average shares outstanding:					
Basic	33,623	32,825	32,881	32,729	29,845
Diluted	33,916	33,667	33,668	33,620	31,448
Balance Sheet Data:					
Working capital	\$ 170,053	118,681	156,808	171,204	174,064
Total assets	660,891	436,485	331,781	314,753	303,945
Long-term debt, net	100,000	25,000	30,026	30,000	30,104
Stockholders' equity	378,937	271,143	233,747	230,735	221,374

- (1) Includes a non-recurring charge of \$5.8 million, net of \$3.6 million tax benefit, related to the cost in excess of revenues of completing fixed fee implementation contracts. The effected tax impact of non-recurring charges on diluted earnings per share was (\$.17) for 1999.
- (2) Includes a non-recurring charge of \$.9 million, net of \$.5 million tax benefit, related to the accrual of branch restructuring costs. The effected tax impact of non-recurring charges on diluted earnings per share was (\$.03) for 1999.
- (3) Includes a non-recurring, acquisition-related charge of \$3.1 million, net of \$1.9 million tax benefit. The tax-effected impact of non-recurring charges on diluted earnings per share was (\$.09) for 1998.

## Summary Financial Data

	<u>1999</u> (1) (2)	<u>1998</u> (3)	<u>1997</u>	<u>1996</u>	<u>1995</u>
<b>(In thousands, except per share data)</b>					
Statements of Earnings Data, Before Non-recurring Charges:					
Revenues	\$ 340,197	330,902	245,057	189,107	186,901
Operating earnings	14,505	38,568	22,170	10,601	37,265
Earnings before income taxes and extraordinary item	11,109	38,306	24,484	12,902	37,220
Extraordinary item – early extinguishment of debt	(1,395)	-	-	-	-
Net earnings	5,462	23,687	15,148	8,251	22,521
Earnings per share before extraordinary item:					
Basic	.20	.72	.46	.25	.75
Diluted	.20	.70	.45	.25	.72
Earnings per share:					
Basic	.16	.72	.46	.25	.75
Diluted	.16	.70	.45	.25	.72
Weighted average shares outstanding:					
Basic	33,623	32,825	32,881	32,729	29,845
Diluted	33,916	33,667	33,668	33,620	31,448
Balance Sheet Data:					
Working capital	\$ 170,053	118,681	156,808	171,204	174,064
Total assets	660,891	436,485	331,781	314,753	303,945
Long-term debt, net	100,000	25,000	30,026	30,000	30,104
Stockholders' equity	378,937	271,143	233,747	230,735	221,374

- (1) Statement of Earnings Data excludes a non-recurring charge of \$5.8 million, net of \$3.6 million tax benefit, related to the cost in excess of revenues of completing fixed fee implementation contracts. The effected tax impact of non-recurring charges on diluted earnings per share was (\$.17) for 1999.
- (2) Statement of Earnings Data excludes a non-recurring charge of \$.9 million, net of \$.5 million tax benefit, related to the accrual of branch restructuring costs. The effected tax impact of non-recurring charges on diluted earnings per share was (\$.03) for 1999.
- (3) Statement of Earnings Data excludes a non-recurring, acquisition-related charge of \$3.1 million, net of \$1.9 million tax benefit. The tax-effected impact of non-recurring charges on diluted earnings per share was (\$.09) for 1998.

## Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

### Introduction

At the beginning of 1999 the Company indicated that 1999 could be a difficult year for the Company due to the possible impact of Y2K issues and the effects of the Balanced Budget Act of 1997 and unfortunately that became true. In both the first and second quarters of 1999 our earnings per share were below expectations. Total revenues declined from the first quarter to the second quarter and from the second quarter to the third quarter, caused by a decline in system sales and new bookings. Potential clients simply could not focus on their Y2K remediation efforts, deal with the decreased funding resulting from the Balanced Budget Act of 1997 and invest in new information systems at the same time. However, beginning in the fourth quarter of 1999 the Company saw significant improvements. Revenue for the fourth quarter was the highest for the year and the second highest quarter ever recorded, bookings in the Company's core business were the highest ever recorded, cash collections increased significantly and non-billed receivables declined to approximately 47% of total receivables, the lowest level since 1996. The increase in revenues and cash collections and the decline in unbilled revenues reflect our success in completing HNA Millennium projects, HNA Millennium market readiness and a declining Y2K impact in the Company's markets.

However, 1999 did mark important accomplishments. The Company met all of its Y2K commitments to clients and the Company's clients have had no Y2K-related problems with the Company's systems. The Company completed the successful implementation of 349 HNA Millennium applications, more than double the number completed during 1997 and 1998, and reduced the average time from project start to conversion from 26.5 months at the end of 1996 to 9.8 months at the end of 1999.

During 2000 patient accounting and other business and management systems, where the Company currently has no or limited market share, will become available. The Company believes HNA Millennium provides a significant competitive advantage because it utilizes the only fully integrated, large scale, enterprise wide architecture in the industry and can deliver a superior combination of functionality, efficiency, cost containment and quality control through interrelated clinical and management information systems. Although the Company believes that there will be some "tail" to the Y2K impact into the year 2000, it also believes that the impact of the Balanced Budget Act of 1997 and the other pressures to decrease costs and provide improved care throughout the healthcare system will stimulate the market for healthcare information systems during the year 2000.

### Results of Operations

#### *Year Ended January 1, 2000, Compared to Year Ended January 2, 1999*

The Company's revenues increased 3% to \$340,197,000 in 1999 from \$330,902,000 in 1998. Net earnings, before extraordinary item and non-recurring charges was \$6,857,000 in 1999 compared to \$23,687,000 in 1998. Non-recurring charges in 1999, as described below, included contract reserves and branch restructuring charges. Non-recurring charges in 1998 include acquisition related charges. Including the extraordinary item and non-recurring charges, the Company incurred a loss of \$1,211,000, in 1999 compared to earnings of \$20,589,000 in 1998.

*Revenues* - In 1999, revenues increased due to an increase in support of installed systems and other revenues. System sales decreased 9% to \$224,510,000 in 1999 from \$245,490,000 in 1998. The decrease in system sales is due to a decrease in new contract bookings in 1999 compared to 1998. The Company believes that this decrease is due primarily to delays in purchasing decisions related to Year 2000 and the Balanced Budget Act of 1997. The sale of additional hardware and software products to the installed client base increased 27% in 1999 as compared to 1998.

Total sales to the installed base in 1999, including new systems, incremental hardware and software, support and maintenance services, and discrete services, were 75% of total revenues in 1999 compared to 69% in 1998. The higher percentage was primarily due to the decrease in system sales to new clients.

At January 1, 2000, the Company had \$338,614,000 in contract backlog and \$162,798,000 in support and maintenance backlog, compared to \$314,965,000 in contract backlog and \$153,453,000 in support and maintenance backlog at the end of 1998.

Support and maintenance revenues increased 23% in 1999 compared to 12% in 1998. These revenues represented 28% of 1999 total revenues and 23% of 1998 total revenues. The higher percentage was primarily attributable to the decrease in system sales and an increase in installed systems.

Other revenues increased 148% to \$21,489,000 in 1999 from \$8,657,000 in 1998. This increase was due primarily to services performed beyond contracted requirements for existing clients. The Company anticipates that other revenues will continue to increase in 2000.

*Cost of Revenues* - The cost of revenues includes the cost of third party consulting services, computer hardware and sublicensed software purchased from computer and software manufacturers for delivery to clients. It also includes the cost of hardware maintenance and sublicensed software support subcontracted to the manufacturers. The cost of revenues was 25% of total revenues in 1999, excluding a non-recurring fixed fee implementation cost, as described below, and 27% of total revenues in 1998. Such costs, as a percent of revenues, typically have varied as the mix of revenue (software, hardware, services and support) components carrying different margin rates changes from period to period. The decrease in the cost of revenue as a percent of total revenues resulted principally from a decrease in the percent of revenue from computer hardware and sublicensed software, which carry a higher cost of revenue percentage.

Included in the 1999 cost of revenues is a charge of \$9,449,000, which represents the remaining additional costs in excess of revenues required to complete certain remaining HNA Millennium fixed fee implementation contracts. The Company switched to an hourly fee-for-service implementation model in 1997. Delays in some of the older projects, primarily caused by delays in development of the Company's HNA Millennium products, increased the time required to complete these installations. While the Company originally anticipated these fixed fee implementations would be completed in 1999, in some instances the focus by clients on their internal Y2K projects created a further delay. As a result of the significant implementation work completed in the last half of 1999 and the agreement between the Company and these clients in the fourth quarter as to the scope of work remaining, the Company estimates that the costs to complete certain fixed fee implementation contracts will exceed the remaining revenue by \$9,449,000. The Company recognized the impact of these excess costs in the fourth quarter income statement as a non-recurring cost of revenues.

*Sales and Client Service* - Sales and client service expenses include salaries of client service personnel, communications expenses, and unreimbursed travel expenses. Also included are sales and marketing salaries, travel expenses, trade show costs, and advertising costs. These expenses as a percent of total revenues were 41% in 1999, excluding a non-recurring charge related to the closing of five branch offices, as described below, and 35% in 1998. The increase in total sales and client service expenses is attributable to the cost of a larger field sales and services organization and marketing of new products.

Included in 1999 sales and client service expenses is a non-recurring charge related to the closing of five branch offices. In December, 1999, the Company made a decision to close five of its branch offices. The Company created a regional branch structure in 1994 in order to bring associates closer to its clients. The natural evolution of that strategy and the ability to leverage internal information technology infrastructure to create a more virtual workplace has resulted in a significant decrease in utilization of certain regional offices. This led to the decision to close these physical locations. The Company recorded a charge of \$1.4 million in the 1999 fourth quarter to provide for the costs of closing these locations, primarily based on estimated lease cancellation fees. The Company will continue to maintain offices in Denver, Detroit and Australia, in addition to the world headquarters in Kansas City, Missouri.

*Software Development* - Software development expenses include salaries, documentation, and other direct expenses incurred in product development and amortization of software development costs. Total expenditures for software development, including both capitalized and noncapitalized portions, for 1999 and 1998 were \$88,699,000 and \$74,159,000, respectively. These amounts exclude amortization. Capitalized software costs were \$30,192,000 and \$25,052,000 for 1999 and 1998, respectively. The increase in aggregate expenditures for software development in 1999 is due to development of *HNA Millennium* products and development of community care products.

*General and Administrative* - General and administrative expenses include salaries for corporate, financial, and administrative staffs, utilities, communications expenses, and professional fees. These expenses as a percent of total revenues were 8% in 1999 and 1998.

*Interest Expense, Net* - Net interest expense was \$3,396,000 in 1999 compared to \$262,000 in 1998. The increase is due to an increase in borrowings. On April 15, 1999, the Company completed a \$100,000,000 private placement of debt pursuant to a Note Agreement date April 1, 1999. The Series A Senior Notes, with a \$60,000,000 principal amount at 7.14% are payable in five equal annual installments beginning in April 2002. The Series B Senior Notes, with a \$40,000,000 principal amount at 7.66% are payable in six equal annual installments beginning April 2004. The proceeds were used to retire the Company's existing \$30,000,000 of debt, and the remaining funds will be used for proposed capital improvements and to strengthen the Company's cash position. In connection with the early extinguishment of debt, the Company incurred a \$1,395,000 net of taxes, extraordinary loss for a prepayment penalty and write-off of deferred loan costs. The note agreement contains certain net worth, current ratio, and fixed charge coverage covenants and provides certain restrictions on the Company's ability to borrow, incur liens, sell assets, and pay dividends. The Company was in compliance with all covenants at January 1, 2000.

*Income Taxes* - The Company's effective tax rate was 39% in 1999 and 38% in 1998.

*Year Ended January 2, 1999, Compared to Year Ended January 3, 1998*

The Company's revenues increased 35% to \$330,902,000 in 1998 from \$245,057,000 in 1997. Net earnings increased 36% to \$20,589,000 in 1998 from \$15,148,000 in 1997. Excluding acquisition related charges, net earnings increased 56% to \$23,687,000 in 1998 relative to 1997.

*Revenues* - In 1998, revenues increased due to an increase in system sales and support of installed systems. System sales increased 44% to \$245,490,000 in 1998 from \$170,906,000 in 1997. This increase in system sales resulted primarily from an increase in installations under *Health Network Architecture* (HNA) contracts. Revenue from HNA contracts increased 23% compared to 1997. The sale of additional hardware and software products to the installed client base increased 30% in 1998 as compared to 1997.

Total sales to the installed base in 1998, including new systems, incremental hardware and software, support and maintenance services, and discrete services, were 69% of total revenues in 1998 compared to 73% in 1997. The lower percentage was primarily due to the increase in system sales to new clients.

At January 2, 1999, the Company had \$314,965,000 in contract backlog and \$153,453,000 in support and maintenance backlog, compared to \$198,274,000 in contract backlog and \$132,842,000 in support and maintenance backlog at the end of 1997.

Support and maintenance revenues increased 12% in 1998 compared to 20% in 1997. These revenues represented 23% of 1998 total revenues and 28% of 1997 total revenues. The lower percentage was primarily due to the increase in system sales.

Other revenues increased 59% to \$8,657,000 in 1998 from \$5,438,000 in 1997. This increase was due primarily to services performed beyond contracted requirements for existing clients.

*Cost of Revenues* - The cost of revenues includes the cost of computer hardware and sublicensed software purchased from computer and software manufacturers for delivery to clients. It also includes the cost of hardware maintenance and sublicensed software support subcontracted to the manufacturers. The cost of revenues was 27% of total revenues in 1998 and 29% of total revenues in 1997. Such costs, as a percent of revenues, typically have varied as the mix of revenue (software, hardware, services and support) components carrying different margin rates changes from period to period. The decrease in the cost of revenue as a percent of total revenues resulted principally from a decrease in the percent of revenue from computer hardware and sublicensed software, which carry a higher cost of revenue percentage.

*Sales and Client Service* - Sales and client service expenses include salaries of client service personnel, communications expenses, and unreimbursed travel expenses. Also included are sales and marketing salaries, travel expenses, trade show costs, and advertising costs. These expenses as a percent of total revenues were 35% in 1998 and 34% in 1997. The increase in total sales and client service expenses is attributable to the cost of a larger field sales and services organization and marketing of new products.

*Software Development* - Software development expenses include salaries, documentation, and other direct expenses incurred in product development and amortization of software development costs. Total expenditures for software development, including both capitalized and noncapitalized portions, for 1998 and 1997 were \$74,159,000 and \$54,524,000, respectively. These amounts exclude amortization. Capitalized software costs were \$25,052,000 and \$18,373,000 for 1998 and 1997, respectively. The increase in aggregate expenditures for software development in 1998 is due to development of *HNA Millennium* products and development of community care products.

*General and Administrative* - General and administrative expenses include salaries for corporate, financial, and administrative staffs, utilities, communications expenses, and professional fees. These expenses as a percent of total revenues were 8% in 1998 and 9% in 1997.

*Write-off of In-Process Research and Development* - Write-off of in-process research and development is a one-time expense resulting from the acquisition of Multum.

*Interest Income (Expense), Net* - Net interest expense was \$262,000 in 1998 compared to net interest income of \$2,314,000 in 1997. The decrease is due primarily to a decrease in invested cash.

*Income Taxes* - The Company's effective tax rate was 38% in 1998 and 1997.

### **Liquidity and Capital Resources**

The Company had total cash and cash equivalents of \$75,677,000 at the end of 1999 and working capital of \$170,053,000, compared to cash and cash equivalents of \$42,658,000 at the end of 1998, and working capital of \$118,681,000. The increase in working capital resulted primarily from the completion of a \$100,000,000 private placement of debt, partially offset by the Company's further investment in software development.

The Company generated cash of \$27,389,000, \$5,893,000, and \$18,692,000 from operations in 1999, 1998, and 1997, respectively. Cash flow from operations increased in 1999, due primarily to increased collection of receivables, improved payment terms, and record level conversions. Cash flow from operations decreased in 1998, due primarily to increases in receivables from increased revenues, and from non-cash consideration received for the sale of license software.

Cash used in investing activities consisted primarily of capitalized software development costs of \$30,192,000 and \$25,052,000 and purchases of capital equipment of \$14,286,000 and \$20,846,000 in 1999 and 1998, respectively. The Company also made additional investments in affiliates in 1999 of \$13,615,000, primarily CareInsite. The major source of cash from financing activities in 1999 was provided by the Company's refinancing of its long-term debt, more fully described in note 6 to the Consolidated Financial Statements. In November 1998, the Company sold 670,000 shares of common stock to General Electric Company, which resulted in cash proceeds of \$14,874,000.

Revenues provided under support and maintenance agreements represent recurring cash flows. Support and maintenance revenues increased 23%, 12%, and 20%, in 1999, 1998, and 1997, respectively, and the Company expects these revenues to continue to grow as the base of installed systems grows.

The Company's liquidity is influenced by many factors, including the amount and timing of the Company's revenues, its cash collections from its clients as implementation of its products proceed and the amounts the Company invests in software development and capital expenditures. The Company expects to have an increase in its cash position for 2000. The Company believes that its present cash position, together with cash generated from operations, will be sufficient to meet anticipated cash requirements during 2000. The Company has an \$18,000,000 line of credit available.

The effects of inflation were minimal on the Company's business.

### **Factors that may Affect Future Results of Operations, Financial Condition or Business**

Statements made in this report, other reports and proxy statements filed with the Securities and Exchange Commission, communications to stockholders, press releases and oral statements made by representatives of the Company that are not historical in nature, or that state the Company's or management's intentions, hopes, beliefs, expectations, or predictions of the future, are "forward-looking statements" within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and involve risks and uncertainties. The words "should," "will be," "intended," "continue," "believe," "may," "expect," "hope," "anticipate," "goal," "forecast" and similar expressions are intended to identify such forward-looking statements. It is important to note that any such performance, and actual results, financial condition or business could differ materially from those expressed in such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below as well as those discussed elsewhere in reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial condition or business over time.

Quarterly Operating Results May Vary - The Company's quarterly operating results have varied in the past and may continue to vary in future periods. Quarterly operating results may vary for a number of reasons including demand for the Company's products and services, the Company's long sales cycle, the long installation and implementation cycle for these larger, more complex and costlier systems and other factors described in this section and elsewhere in this report. As a result of healthcare industry trends and the market for the Company's HNA Millennium products, a large percentage of the Company's revenues are generated by the sale and installation of larger, more complex and costlier systems. The sales process for these systems is lengthy and involves a significant technical evaluation and commitment of capital and other resources by the customer. The sale may be subject to delays due to customers' internal budgets and procedures for approving large capital expenditures and by competing needs for other capital expenditures and deploying new technologies or personnel resources. Delays in the expected sale or installation of these large contracts may have a significant impact on the Company's anticipated quarterly revenues and consequently its earnings, since a significant percentage of the Company's expenses are relatively fixed.

These larger, more complex and costlier systems are installed and implemented over time periods ranging from approximately six months to three years and involve significant efforts both by the Company and the client. In addition, implementation of the Company's HNA Millennium products is a new and evolving process. The Company recognizes revenue upon the completion of standard milestone conditions and the amount of revenue recognized in any quarter depends upon the Company's and the client's ability to meet these project milestones. Delays in meeting these milestone conditions or modification of the contract relating to one or more of these systems could result in a shift of revenue recognition from one quarter to another and could have a material adverse effect on results of operations for a particular quarter. In addition, support payments by clients for the Company's products do not commence until the product is in use.

The Company's revenues from system sales historically have been lower in the first quarter of the year and greater in the fourth quarter of the year.

Stock Price May Be Volatile - The trading price of the Company's common stock may be volatile. The market for the Company's common stock may experience significant price and volume fluctuations in response to a number of factors including actual or anticipated quarterly variations in operating results, changes in expectations of future financial performance or changes in estimates of securities analysts, governmental regulatory action, healthcare reform measures, client relationship developments and other factors, many of which are beyond the Company's control.

Furthermore, the stock market in general, and the market for software, healthcare and high technology companies in particular, has experienced extreme volatility that often has been unrelated to the operating performance of particular companies. These broad market and industry fluctuations may adversely affect the trading price of the Company's common stock, regardless of actual operating performance.

Market Risk of Investments - The Company accounts for its investments in equity securities which have readily determinable fair values as available-for-sale. Available-for-sale securities are reported at fair value with unrealized gains and losses reported, net of tax, as a separate component of accumulated other comprehensive income. Investments in the common stock of certain affiliates over which the Company exerts significant influence are accounted for by the equity method. Investments in other equity securities are reported at cost. All equity securities are reviewed by the Company for declines in fair value. If such declines are considered to be other than temporary, the cost basis of the individual security is written down to fair value as a new cost basis, and the amount of the write-down is included in earnings.

Included in the Company's investments is the ownership of 13,149,259 shares (18.7%) of the common stock of CareInsite, Inc. ("CareInsite"), formerly known as Syntec Healthcare Communications, Inc. which have a cost basis of \$81,804,000 and a carrying value of \$248,821,000 at January 1, 2000. 12,437,500 of these shares were received in 1998 as consideration for the sale of licensed software, and an additional 711,759 shares were purchased in 1999. The value assigned to the shares acquired in 1998 was \$70,000,000 and was based on a methodology which utilized both a comparable company and the expected underlying discounted future cash flows. On June 16, 1999, CareInsite undertook an initial public offering of common stock. The common stock of CareInsite is traded in the public market and listed on the Nasdaq National Market. The stock of CareInsite held by the Company is not registered and is subject to certain lock-up provisions. A permanent impairment in the value of CareInsite common stock would result in a charge to earnings in either the then current or future periods. There would be no effect on cash flows because the revenue was earned through contractual rights granted in exchange for CareInsite stock. An increase in the value of the CareInsite stock would have no effect on reported earnings. The Company has not engaged in equity swaps or other hedging techniques to manage the equity risk inherent in the CareInsite shares.

Under Statement of Financial Accounting Standards no. 115 "Accounting for Certain Investments in Debt and Equity Securities" (SFAS No. 115), the Company is required to mark to market those shares which are classified as available-for-sale. Additionally, SFAS No. 115 requires shares that are eligible under Rule 144 for public sale within a twelve month period be considered as available-for-sale. Under Rule 144, as currently in effect, a person who has beneficially owned shares of common stock for at least one year would be entitled to sell within any three-month period a number of shares that does not exceed the greater of 1% of the number of shares of common stock then outstanding and the average weekly trading volume of the common stock during the four preceding calendar weeks. As of January 1, 2000, the Company has marked to market 2,230,700 shares of CareInsite common stock, with a market value of \$179,571,000, that are considered available-for-sale under Rule 144 and SFAS No. 115. All CareInsite shares the Company owns will be considered available-for-sale and be marked to market in the first quarter of 2000. If all shares were eligible to be marked to market at January 1, 2000, the market value would be \$1,058,515,000.

If the Company realizes certain performance metrics related to specified levels of physician usage, CareInsite will issue to the Company 2,503,125 shares of common stock at a price of \$.01 per share ("Performance Shares"). The measurement date is February 15, 2001. No amounts have been recognized in the consolidated financial statements for the Performance Shares due to the uncertainty of the future events.

The Company was also granted, by CareInsite, 1,008,445 common stock warrants with an exercise price of \$4.00 per share ("THINC Warrants"). The THINC Warrants were exercisable only in the event that The Health Information Network Connections, LLC ("THINC") exercised warrants granted to them by CareInsite at \$4.00 per share. THINC was allowed to exercise their warrants 180 days after the initial public offering of CareInsite. On January 29, 2000 CareInsite completed an acquisition of THINC. As part of that agreement, 806,756 of the 1,008,445 THINC Warrants became immediately exercisable, with the remaining amount forfeited. The THINC Warrants expire in three years.

On February 13, 2000 CareInsite entered into an agreement to merge with Healtheon/WebMD Corporation ("Merger Agreement"). As part of the Merger Agreement, the Company will receive 1.3 shares of Healtheon/WebMD Corporation in exchange for each common share of CareInsite held by the Company. In addition the Performance Shares will be adjusted at a rate of 1.3 shares of Healtheon/WebMD Corporation for each share of CareInsite. All physician users of systems of Healtheon/WebMD Corporation or its affiliates shall be included for purposes of determining the specified levels of physician usage. The THINC Warrants will also be adjusted at a rate of 1.3 shares of Healtheon/WebMD Corporation for each share of CareInsite. The proposed merger of CareInsite and Healtheon/WebMD Corporation ("Merger") is subject to shareholder and regulatory approval. There is no guarantee the Merger will close.

The Company has agreed under terms of the Merger Agreement to certain lock-up provisions, which differ from the terms of its lock-up provisions with CareInsite. The Merger is expected to close in the second quarter of 2000. If the Merger closes the Company will record the Healtheon/WebMD Corporation shares received at their then fair value and recognize a gain on the disposition of the CareInsite shares. Based on proposed lock-up provisions, 50% of the Healtheon/WebMD Corporation shares would thereafter be considered available-for-sale and would be marked to market at each balance sheet date. The remainder would be carried at cost until the third quarter of 2000.



The Company owns 50% of Health Network Ventures (“HNV”), a joint venture investment which is accounted for under the equity method. Under the terms of the joint venture agreement, the Company may require its partner to sell to the Company its share of HNV for \$12,000,000, subject to certain adjustments, (“Call Option”) at any time after July 1, 2000. In addition the partner may require the Company to purchase its share of HNV for \$6,000,000, subject to certain adjustments, (“Put Option”) at any time after July 1, 2000.

The Company is exposed to market risk from changes in marketable securities (which consist of money market and commercial paper). At January 1, 2000, marketable securities of the Company were recorded at cost, which approximates fair value of approximately \$76 million, with an overall average return of approximately 5% and an overall weighted maturity of less than 90 days. The marketable securities held by the Company are not subject to price risk as a result of the short-term nature of the investments.

The Company is not exposed to material future earnings or cash flow exposures from changes in interest rates on long-term debt since 100% of its long-term debt is at a fixed rate. To date, the Company has not entered into any derivative financial instruments to manage interest rate risk.

The Company conducts business in several foreign jurisdictions. However, the business transacted is in the local functional currency and the Company does not currently have any material exposure to foreign currency transaction gains or losses. All other business transactions are in U.S. dollars. To date, the Company has not entered into any derivative financial instrument to manage foreign currency risk and is currently not evaluating the future use of any such financial instruments.

Changes in the Healthcare Industry - The healthcare industry is highly regulated and is subject to changing political, economic and regulatory influences. For example, the Balanced Budget Act of 1997 (Public Law 105-32) contains significant changes to Medicare and Medicaid and began to have its initial impact in 1998 due to limitations on reimbursement, resulting cost containment initiatives, and effects on pricing and demand for capital intensive systems. These factors affect the purchasing practices and operation of healthcare organizations. Federal and state legislatures have periodically considered programs to reform or amend the U.S. healthcare system at both the federal and state level and to change healthcare financing and reimbursement systems. These programs may contain proposals to increase governmental involvement in healthcare, lower reimbursement rates or otherwise change the environment in which healthcare industry participants operate. Healthcare industry participants may respond by reducing their investments or postponing investment decisions, including investments in the Company's products and services.

Many healthcare providers are consolidating to create integrated healthcare delivery systems with greater market power. These providers may try to use their market power to negotiate price reductions for the Company's products and services. As the healthcare industry consolidates, the Company's customer base could be eroded, competition for customers could become more intense and the importance of acquiring each customer becomes greater.

Significant Competition - The market for healthcare information systems is intensely competitive, rapidly evolving and subject to rapid technological change. The Company believes that the principal competitive factors in this market include the breadth and quality of system and product offerings, the stability of the information systems provider, the features and capabilities of the information systems, the ongoing support for the system, and the potential for enhancements and future compatible products.

Certain of the Company's competitors have greater financial, technical, product development, marketing and other resources than the Company and some of its competitors offer products that it does not offer. The Company's principal existing competitors include Shared Medical Systems Corporation, IDX Systems Corporation, McKesson HBOC, Inc. and Eclipsys Corporation, each of which offers a suite of products that compete with many of the Company's products. There are other competitors that offer a more limited number of competing products.

In addition, the Company expects that major software information systems companies, large information technology consulting service providers and system integrators, internet-based start-up companies and others specializing in the healthcare industry may offer competitive products or services. The pace of change in the healthcare information systems market is rapid and there are frequent new product introductions, product enhancements and evolving industry standards and requirements. As a result, the Company's success will depend upon its ability to keep pace with technological change and to introduce, on a timely and cost-effective basis, new and enhanced products that satisfy changing customer requirements and achieve market acceptance.

Proprietary Technology May Be Subjected to Infringement Claims or May Be Infringed Upon - The Company relies upon a combination of trade secret, copyright and trademark laws, license agreements, confidentiality procedures, employee nondisclosure agreements and technical measures to maintain the trade secrecy of its proprietary information. The Company has not historically filed patent applications or copyrights covering its software technology. As a result, the Company may not be able to protect against misappropriation of its intellectual property.

In addition, the Company could be subject to intellectual property infringement claims as the number of competitors grows and the functionality of its products overlaps with competitive offerings. These claims, even if not meritorious, could be expensive to defend. If the Company becomes liable to third parties for infringing their intellectual property rights, it could be required to pay a substantial damage award and to develop noninfringing technology, obtain a license or cease selling the products that contain the infringing intellectual property.

Government Regulation - The United States Food and Drug Administration (the "FDA") has declared that software products intended for the maintenance of data used in making decisions regarding the suitability of blood donors and the release of blood or blood components for transfusion are medical devices under the Federal Food, Drug and Cosmetic Act ("Act") and amendments to the Act. As a consequence, the Company is subject to extensive regulation by the FDA with regard to its blood bank software. If other of the Company's products are deemed to be actively regulated medical devices by the FDA, the Company could be subject to extensive requirements governing pre- and post-marketing requirements including premarket notification clearance prior to marketing. Complying with these FDA regulations would be time consuming and expensive. It is possible that the FDA may become more active in regulating computer software that is used in healthcare.

Following an inspection by the FDA in March of 1998, the Company received a Form FDA 483 (Notice of Inspectional Observations) alleging non-compliance with certain aspects of FDA's Quality System Regulation with respect to the Company's PathNet HNAC Blood Bank Transfusion and Donor products (the "Blood Bank Products"). The Company subsequently received a Warning Letter, dated April 29, 1998, as a result of the same inspection. The Company responded promptly to the FDA and undertook a number of actions in response to the Form 483 and Warning Letter including an audit by a third party of the Company's Blood Bank Products and improvements to Cerner's Quality System. A copy of the third party audit was submitted to the FDA in October of 1998 and, at the request of the FDA, additional information and clarification was submitted to the FDA in January of 1999.

There can be no assurance, however, that the Company's actions taken in response to the Form 483 and Warning Letter will be deemed adequate by the FDA or that additional actions on behalf of the Company will not be required. In addition, the Company remains subject to periodic FDA inspections and there can be no assurances that the Company will not be required to undertake additional actions to comply with the Act and any other applicable regulatory requirements. Any failure by the Company to comply with the Act and any other applicable regulatory requirements could have a material adverse effect on the Company's ability to continue to manufacture and distribute its products. FDA has many enforcement tools including recalls, seizures, injunctions, civil fines and/or criminal prosecutions. Any of the foregoing would have a material adverse effect on the Company's business, results of operations or financial condition.

Product Related Liabilities - Many of the Company's products provide data for use by healthcare providers in providing care to patients. Although no such claims have been brought against the Company to date regarding injuries related to the use of its products, such claims may be made in the future. Although the Company maintains product liability insurance coverage in an amount that it believes is sufficient for its business, there can be no assurance that such coverage will prove to be adequate or that such coverage will continue to remain available on acceptable terms, if at all. A successful claim brought against the Company which is uninsured or under-insured could materially harm its business, results of operations or financial condition.

System Errors and Warranties - The Company's systems, particularly the HNA Millennium versions, are very complex. As with complex systems offered by others, the Company's systems may contain errors, especially when first introduced. Although the Company conducts extensive testing, it has discovered software errors in its products after their introduction. The Company's systems are intended for use in collecting and displaying clinical information used in the diagnosis and treatment of patients. Therefore, users of the Company products have a greater sensitivity to system errors than the market for software products generally. The Company's agreements with its clients typically provide warranties against material errors and other matters. Failure of a client's system to meet these criteria could constitute a material breach under such contracts allowing the client to cancel the contract, or could require the Company to incur additional expense in order to make the system meet these criteria. The Company's contracts with its clients generally limit the Company's liability arising from such claims but such limits may not be enforceable in certain jurisdictions.

Anti-Takeover Defenses - The Company's charter, bylaws, shareholders' rights plan and certain provisions of Delaware law contain certain provisions that may have the effect of delaying or preventing an acquisition of the Company. Such provisions are intended to encourage any person interested in acquiring the Company to negotiate with and obtain the approval of the Board of Directors in connection with any such transaction. These provisions include (i) a Board of Directors that is staggered into three classes to serve staggered three-year terms, (ii) blank check preferred stock, (iii) supermajority voting provisions, (iv) inability of stockholders to act by written consent or call a special meeting, (v) limitations on the ability of stockholders to nominate directors or make proposals at stockholder meetings, and (vi) triggering the exercisability of stock purchase rights on a discriminatory basis, which may invoke extensive economic and voting dilution of a potential acquirer if its beneficial ownership of the Company's common stock exceeds a specified threshold. Certain of these provisions may discourage a future acquisition of the Company not approved by the Board of Directors in which shareholders might receive a premium value for their shares.

Year 2000 - As of the date of this annual report, the Company has not seen any adverse impact as a result of the Year 2000 transition on any of its systems or those of its clients or suppliers. Nonetheless, the Company will continue to monitor the effect of the Year 2000 transition, and there can be no absolute assurance that Year 2000 issues will not materialize in the future and have a material adverse effect on the Company, its products or its operations.

## **Item 7A. Quantitative and Qualitative Disclosures about Market Risk**

Information contained under the caption "Factors that may Affect Future Results of Operations, Financial Condition or Business — Market Risk of Investments" set forth under "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Item 7 is incorporated herein by reference.

## **Item 8. Financial Statements and Supplementary Data**

The Financial Statements and Notes required by this Item are submitted as a separate part of this report.

## **Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure**

None.

## **PART III**

## **Item 10. Directors and Executive Officers of the Registrant**

The Registrant's Proxy Statement to be used in connection with the Annual Meeting of Stockholders to be held on May 26, 2000, contains under the caption "Election of Directors" certain information required by Item 10 of Form 10-K and such information is incorporated herein by this reference. The information required by Item 10 of Form 10-K as to executive officers is set forth in Item 4A of Part I hereof.

The Registrant's Proxy Statement to be used in connection with the Annual Meeting of Stockholders to be held on May 26, 2000, contains under the caption "Compliance with Section 16(a) of the Securities Exchange Act of 1934" certain information required by Item 10 of Form 10-K and such information is incorporated herein by this reference.

## **Item 11. Executive Compensation**

The Registrant's Proxy Statement to be used in connection with the Annual Meeting of Stockholders to be held on May 26, 2000, contains under the caption "Executive Compensation" the information required by Item 11 of Form 10-K and such information is incorporated herein by this reference.

## **Item 12. Security Ownership of Certain Beneficial Owners and Management**

The Registrant's Proxy Statement to be used in connection with the Annual Meeting of Stockholders to be held on May 26, 2000, contains under the caption "Voting Securities and Principal Holders Thereof" the information required by Item 12 of Form 10-K and such information is incorporated herein by this reference.

## **Item 13. Certain Relationships and Related Transactions**

The Registrant's Proxy Statement to be used in connection with the Annual Meeting of Stockholders to be held on May 26, 2000, contains under the caption "Certain Transactions" the information required by Item 13 of Form 10-K and such information is incorporated herein by this reference.

**PART IV**

**Item 14. Exhibits, Financial Statement Schedules, and Reports on Form 8-K**

- (a) Financial Statements.
  - (1) Consolidated Financial Statements:
    - Independent Auditors' Report on Consolidated Financial Statements
    - Consolidated Balance Sheets -  
January 1, 2000 and January 2, 1999
    - Consolidated Statements of Operations -  
Years Ended January 1, 2000, January 2, 1999 and January 3, 1998
    - Consolidated Statements of Changes In Equity  
Years Ended January 1, 2000, January 2, 1999 and January 3, 1998
    - Consolidated Statements of Cash Flows  
Years Ended January 1, 2000, January 2, 1999 and January 3, 1998
    - Notes to Consolidated Financial Statements
  - (2) The following financial statement, schedule and independent auditors' report on financial statement schedule of the Registrant for the three-year period ended January 1, 2000 are included herein:
    - Schedule II - Valuation and Qualifying Accounts,
    - Independent Auditors' Report on Consolidated Financial Statement Schedule.

All other schedules are omitted, as the required information is inapplicable or the information is presented in the consolidated financial statements or related notes.

- (3) The exhibits required to be filed by this item are set forth below:

<u>Number</u>	<u>Description</u>
3(a)	Restated Certificate of Incorporation of the Registrant, (filed as Exhibit 3(i) to Registrant's Quarterly Report on Form 10-Q for the year ended June 29, 1996 and hereby incorporated by reference).
3(b)	Bylaws, as amended (filed as Exhibit 3 to the Registrant's Quarterly Report on Form 10-Q for the six months ended June 30, 1995, and hereby incorporated by reference).

- 4(a) Amended and Restated Rights Agreement, dated as of March 12, 1999, between Cerner Corporation and UMB Bank, n.a., as Rights Agents, which includes the Form of Certificate of Designation, Preferences and Rights of Series A Preferred Stock of Cerner Corporation, as Exhibit A, and the Form of Rights Certificate, as Exhibit B (filed as an Exhibit to Registrant's current report on Form 8-A/A dated March 31, 1999 and incorporated herein by reference).
- 4(b) Specimen stock certificate (filed as Exhibit 4(a) to Registrant's Registration Statement on Form S-8 (File No. 33-15156) and hereby incorporated herein by reference).
- 4(c) Credit Agreement between Cerner Corporation and Mercantile Bank dated April 1, 1999 (filed as Exhibit 4(d) to Registrant's Annual Report on Form 10-K for the year ended January 2, 1999, and hereby incorporated herein by reference).
- 10(a) Incentive Stock Option Plan C of Registrant (filed as Exhibit 10(f) to Registrant's Annual Report on Form 10-K for the year ended December 31, 1993, and hereby incorporated herein by reference).\*
- 10(b) Indemnification Agreements between the Registrant and Neal L. Patterson, Clifford W. Illig, Gerald E. Bisbee, Jr., Ph.D. and Thomas C. Tinstman, M.D., (filed as Exhibit 10(i) to Registrant's Annual report on Form 10-K for the year ended December 31, 1992, and incorporated herein by reference).\*
- 10(c) Indemnification Agreement between Michael E. Herman and Registrant (filed as Exhibit 10(i)(a) to Registrant's Quarterly Report on Form 10-Q for the year ended June 29, 1996 and hereby incorporated by reference).\*
- 10(d) Indemnification Agreement between John C. Danforth, and Registrant (filed as Exhibit 10(i)(b) to Registrant's Quarterly Report on Form 10-Q for the year ended June 29, 1996 and hereby incorporated by reference).\*
- 10(e) Indemnification Agreement between Jeff C. Goldsmith, Ph.D. and Registrant.\*
- 10(f) Amended Stock Option Plan D of Registrant (filed as Exhibit 10 (g) to Registrant's Annual Report on Form 10-K for the year ended January 3, 1998, and hereby incorporated by reference).\*
- 10(g) Stock Option Plan E of Registrant (filed as Exhibit 10(h) to Registrant's Annual Report on Form 10-K for the year ended January 3, 1998, and hereby incorporated by reference).\*
- 10(h) Cerner Performance Plan for 1999 (filed as Exhibit 10(j) to Registrant's Annual Report on Form 10-K for the year ended January 2, 1999, and hereby incorporated herein by reference).\*
- 10(i) Cerner Performance Plan for 2000.\*
- 10(j) Long-Term Incentive Plan for 1999 (filed as Exhibit 10(l) to Registrant's Annual Report on Form 10-K for the year ended January 2, 1999, and hereby incorporated herein by reference).\*
- 10(k) Promissory Note of Jack A. Newman, Jr. (filed as Exhibit 10(m) to Registrant's Annual Report on Form 10-K for the year ended January 2, 1999, and hereby incorporated herein by reference).\*
- 10(l) Promissory Notes of Earl H. Devanny, III.\*
- 10(m) Promissory Note of Glenn P. Tobin, Ph.D. (filed as Exhibit 10(o) to Registrant's Annual Report on Form 10-K for the year ended January 2, 1999, and hereby incorporated herein by reference).\*
- 10 (n) Cerner Corporation Executive Stock Purchase Plan (filed as Exhibit 4(g) to Registrant's Registration Statement on Form S-8 (File No. 333-77029) and hereby incorporated herein by reference).\*
- 10(o) Form of Stock Pledge Agreement for Cerner Corporation Executive Stock Purchase Plan (filed as Exhibit 4(h) to Registrant's Registration Statement on Form S-8 (File No. 333-77029) and hereby incorporated herein by reference).\*
- 10(p) Form of Promissory Note for Cerner Corporation Executive Stock Purchase Plan (filed as Exhibit 4(i) to Registrant's Registration Statement on Form S-8 (File No. 333-77029) and hereby incorporated herein by reference).\*
- 10(q) Employment Agreement of Earl H. Devanny, III.\*

10(r)	Employment Agreement of Glenn P. Tobin, Ph.D.*
10(s)	Employment Agreement of Stanley M. Sword.*
11	Computation of Registrant's Earnings Per Share. (Exhibit omitted. Information contained in notes to consolidated financial statements.)
21	Subsidiaries of Registrant.
23	Consent of Independent Auditors.
27	Financial Data Schedule.

\* Management contracts or compensatory plans or arrangements required to be identified by Item 14(a)(3).

(b) Reports on Form 8-K

Reports on form 8-K were filed on March 18, 1999, April 23, 1999 and September 28, 1999.

(c) Exhibits.

The response to this portion of Item 14 is submitted as a separate section of this report.

(d) Financial Statement Schedules.

The response to this portion of Item 14 is submitted as a separate section of this report.

## SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CERNER CORPORATION

Dated: March 27, 2000

By: /s/ Neal L. Patterson  
Neal L. Patterson  
Chairman of the Board and  
Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

<u>Signature and Title</u>	<u>Date</u>
<u>/s/Neal L. Patterson</u> Neal L. Patterson, Chairman of the Board and Chief Executive Officer (Principal Executive Officer)	March 27, 2000
<u>/s/Clifford W. Illig</u> Clifford W. Illig, Vice Chairman and Director	March 27, 2000
<u>/s/Marc G. Naughton</u> Marc G. Naughton, Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)	March 27, 2000
<u>/s/Michael E. Herman</u> Michael E. Herman, Director	March 27, 2000
<u>/s/Gerald E. Bisbee</u> Gerald E. Bisbee, Jr., Ph.D., Director	March 27, 2000
<u>/s/Thomas C. Tinstman</u> Thomas C. Tinstman, M.D., Senior Vice President and Director	March 27, 2000
<u>/s/John C. Danforth</u> John C. Danforth, Director	March 27, 2000
<u>/s/ Jeff C. Goldsmith</u> Jeff C. Goldsmith, Ph.D., Director	March 27, 2000

## **Independent Auditors' Report**

---

The Board of Directors and Stockholders  
Cerner Corporation:

We have audited the accompanying consolidated balance sheets of Cerner Corporation and subsidiaries as of January 1, 2000 and January 2, 1999, and the related consolidated statements of operations, changes in equity, and cash flows for each of the years in the three-year period ended January 1, 2000. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Cerner Corporation and subsidiaries as of January 1, 2000 and January 2, 1999, and the results of their operations and their cash flows for each of the years in the three-year period ended January 1, 2000, in conformity with generally accepted accounting principles.

**KPMG LLP**

Kansas City, Missouri  
February 14, 2000

## **Management's Report**

---

The management of Cerner Corporation is responsible for the consolidated financial statements and all other information presented in this report. The financial statements have been prepared in conformity with generally accepted accounting principles appropriate to the circumstances, and, therefore, included in the financial statements are certain amounts based on management's informed estimates and judgments. Other financial information in this report is consistent with that in the consolidated financial statements. The consolidated financial statements have been audited by Cerner Corporation's independent certified public accountants and have been reviewed by the audit committee of the Board of Directors.



## Consolidated Balance Sheets

January 1, 2000 and January 2, 1999

	1999	1998
(Dollars in thousands)		
Assets		
Current Assets:		
Cash and cash equivalents	\$ 75,677	42,658
Receivables	161,174	167,374
Inventory	1,262	2,651
Prepaid expenses and other	4,316	4,234
Total current assets	242,429	216,917
Property and equipment, net	77,938	77,292
Software development costs, net	71,007	54,971
Intangible assets, net	7,511	8,884
Investments, net	252,123	71,719
Other assets	9,883	6,702
	\$ 660,891	436,485
Liabilities and Stockholders' Equity		
Current Liabilities:		
Accounts payable	\$ 20,261	14,092
Current installments of long-term debt	-	5,030
Deferred revenue	21,245	33,921
Income taxes	10,987	26,057
Accrued payroll and tax withholdings	17,241	16,625
Other accrued expenses	2,642	2,511
Total current liabilities	72,376	98,236
Long-term debt, net	100,000	25,000
Deferred income taxes	93,578	22,106
Deferred revenue	16,000	20,000
Stockholders' Equity:		
Common stock, \$.01 par value, 150,000,000 shares authorized, 34,932,703 shares issued in 1999 and 34,674,164 shares in 1998	349	347
Additional paid-in capital	166,735	165,239
Retained earnings	125,651	126,862
Treasury stock, at cost (1,201,518 shares in 1999 and 1998)	(20,796)	(20,796)
Accumulated other comprehensive income:		
Foreign currency translation adjustment	23	(243)
Unrealized gain (loss) on available-for-sale equity securities (net of deferred tax liability of \$59,806 in 1999 and deferred tax asset of \$165 in 1998)	106,975	(266)
Total stockholders' equity	378,937	271,143
Commitments (Note 12)	\$ 660,891	436,485

See notes to consolidated financial statements.

## Consolidated Statements of Operations

For the years ended January 1, 2000, January 2, 1999, and January 3, 1998

	1999	1998	1997
(In thousands, except per share data)			
Revenues			
System sales	\$ 224,510	245,490	170,906
Support and maintenance	94,198	76,755	68,713
Other	21,489	8,657	5,438
Total revenues	340,197	330,902	245,057
Costs and expenses			
Cost of revenues	95,038	89,544	71,943
Sales and client service	141,234	117,107	83,788
Software development	72,663	59,754	44,086
General and administrative	27,564	25,929	23,070
Write-off of acquired in-process research and development	-	5,038	-
Total costs and expenses	336,499	297,372	222,887
Operating earnings	3,698	33,530	22,170
Interest income (expense), net	(3,396)	(262)	2,314
Earnings before income taxes and extraordinary item	302	33,268	24,484
Income taxes	(118)	(12,679)	(9,336)
Earnings before extraordinary item	184	20,589	15,148
Extraordinary item, net of tax	(1,395)	-	-
Net earnings (loss)	\$ (1,211)	20,589	15,148
Basic earnings per share before extraordinary item	\$ .01	.63	.46
Basic earnings (loss) per share	\$ (.04)	.63	.46
Diluted earnings per common share before extraordinary item	\$ .01	.61	.45
Diluted earnings (loss) per common share	\$ (.04)	.61	.45

See notes to consolidated financial statements.

## Consolidated Statements of Changes in Equity

For the years ended January 1, 2000, January 2, 1999, and January 3, 1998

	Common Stock Shares	Common Stock Amount	Additional paid-in capital	Retained earnings	Treasury stock amount	Accumulated other Comprehensive income	Comprehensive income
(In thousands)							
Balance at December 28, 1996	33,404	\$ 334	144,941	91,125	(5,693)	28	
Exercise of options	311	3	978	-	-	-	
Issuance of common stock grants as compensation	2	-	48	-	-	-	
Issuance of restricted common stock	100	1	1,586	-	-	-	
Tax benefit from disqualifying disposition of stock options	-	-	521	-	-	-	
Purchase of 688,500 shares of treasury stock	-	-	-	-	(15,103)	-	
Foreign currency translation adjustment	-	-	-	-	-	(170)	(170)
Net earnings	-	-	-	15,148	-	-	15,148
Comprehensive income							14,978
Balance at January 3, 1998	33,817	338	148,074	106,273	(20,796)	(142)	
Exercise of options	185	2	1,248	-	-	-	
Issuance of common stock grants as compensation	2	-	44	-	-	-	
Issuance of common stock	670	7	14,867	-	-	-	
Non-employee stock option compensation expense	-	-	385	-	-	-	
Tax benefit from disqualifying disposition of stock options	-	-	621	-	-	-	
Foreign currency translation adjustment	-	-	-	-	-	(101)	(101)
Unrealized loss on available-for-sale equity security, net of deferred tax asset of \$165	-	-	-	-	-	(266)	(266)
Net earnings	-	-	-	20,589	-	-	20,589
Comprehensive income							20,222
Balance at January 2, 1999	34,674	347	165,239	126,862	(20,796)	(509)	
Exercise of options	257	2	623	-	-	-	
Issuance of common stock grants as compensation	2	-	40	-	-	-	
Non-employee stock option compensation expense	-	-	239	-	-	-	
Tax benefit from disqualifying disposition of stock options	-	-	594	-	-	-	
Foreign currency translation adjustment	-	-	-	-	-	266	266
Unrealized gain on available-for-sale equity securities, net of deferred tax liability of \$59,806	-	-	-	-	-	107,241	107,241
Net loss	-	-	-	(1,211)	-	-	(1,211)
Comprehensive income							106,296
Balance at January 1, 2000	34,933	\$ 349	166,735	125,651	(20,796)	106,998	

See notes to consolidated financial statements.

## Consolidated Statements of Cash Flows

For the years ended January 1, 2000, January 2, 1999, and January 3, 1998

(In thousands)	1999	1998	1997
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Net earnings (loss)	\$ (1,211)	20,589	15,148
Adjustments to reconcile net earnings (loss) to net cash provided by operating activities:			
Depreciation and amortization	31,388	25,411	18,075
Common stock received as consideration for sale of license software	-	(70,000)	-
Non-recurring fixed fee implementation cost	9,449	-	-
Non-recurring branch restructure charge	1,358	-	-
Extraordinary item, net of tax	1,395	-	-
Write-off of acquired in-process research and development	-	5,038	-
Issuance of common stock grants as compensation	40	44	48
Non-employee stock option compensation expense	239	385	-
Equity in losses of affiliates	423	1,601	864
Provision for deferred income taxes	(3,165)	15,816	8,246
Tax benefit from disqualifying dispositions of stock options	594	621	521
Loss on disposal of capital equipment	478	223	110
Changes in operating assets and liabilities (net of business acquired):			
Receivables, net	6,200	(39,481)	(27,931)
Inventory	1,389	(908)	(127)
Prepaid expenses and other	844	(3,970)	(2,075)
Accounts payable	(5,207)	2,620	1,984
Accrued income taxes	461	(2,334)	-
Deferred revenue	(16,676)	45,410	479
Other current liabilities	(610)	4,828	3,350
Total adjustments	28,600	(14,696)	3,544
Net cash provided by operating activities	27,389	5,893	18,692
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Purchase of capital equipment	(14,286)	(20,846)	(14,896)
Purchase of land, buildings, and improvements	-	(2,767)	(86)
Acquisition of business	-	(6,874)	-
Investment in affiliates	(13,615)	(1,217)	(4,500)
Advances to affiliates	(1,000)	-	-
Executive stock purchase program	(3,628)	-	-
Proceeds on disposal of capital equipment	59	-	212
Capitalized software development costs	(30,192)	(25,052)	(18,373)
Net cash used in investing activities	(62,662)	(56,756)	(37,643)
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Proceeds from issuance of long-term debt	99,568	-	-
Repayment of long-term debt	(32,167)	(45)	(116)
Proceeds from sale of common stock	-	14,874	-
Proceeds from exercise of options	625	1,250	981
Purchase of treasury stock	-	-	(15,103)
Net cash provided by (used in) financing activities	68,026	16,079	(14,238)
Foreign currency translation adjustment	266	(101)	(170)
Net increase (decrease) in cash and cash equivalents	33,019	(34,885)	(33,359)
Cash and cash equivalents at beginning of year	42,658	77,543	110,902
Cash and cash equivalents at end of year	\$ 75,677	42,658	77,543
<b>Supplemental disclosures of cash flow information</b>			
Cash paid (received) during the year for:			
Interest	\$ 5,448	2,504	2,473
Income taxes, net of refund	1,647	(2,112)	1,024
<b>Noncash investing and financing activities</b>			
Issuance of restricted common stock and grants	40	44	1,635

See notes to consolidated financial statements.

## Notes to Consolidated Financial Statements

---

### 1 Summary of Significant Accounting Policies

(a) **Principles of Consolidation** - The consolidated financial statements include the accounts of Cerner Corporation and its wholly owned subsidiaries (the Company). All significant intercompany transactions and balances have been eliminated in consolidation.

(b) **Revenue Recognition** - Revenues are derived primarily from the sale of clinical information systems. The Company also provides project implementation and consulting services. In addition, revenue is generated from servicing installed clinical information systems, which generally includes support of software and maintenance of hardware. The Company also derives revenue from the sale of computer hardware.

Clinical information system sales contracts are negotiated separately and generally include the licensing of the Company's clinical information system software, project-related services associated with the installation of the systems, and the sale of computer hardware. Clinical information system sales contracts are noncancelable and provide for a right of return only in the event the system fails to meet the performance criteria set forth in the contracts. The Company recognizes revenue from sales of clinical information systems using a percentage-of-completion method based on meeting key milestone events over the term of the contracts in accordance with Statement of Position 97-2, "Software Revenue Recognition". Revenue recognized is limited to amounts to be billed within one year.

Revenue associated with project implementation and consulting services is recognized as the services are performed. Revenue from the licensing of additional software is recognized upon installation at the client's site. Revenue from the sale of computer hardware is recognized upon shipment. Revenue from ongoing software support and equipment maintenance is recognized as the services are rendered.

(c) **Fiscal Year** - The Company's fiscal year ends on the Saturday closest to December 31. Fiscal years 1999 and 1998, respectively, consisted of 52 weeks each, and fiscal year 1997 consisted of 53 weeks. All references to years in these notes to consolidated financial statements represent fiscal years unless otherwise noted.

(d) **Software Development Costs** - Costs incurred internally in creating computer software products are expensed until technological feasibility has been established upon completion of a detail program design. Thereafter, all software development costs are capitalized and subsequently reported at the lower of amortized cost or net realizable value. Capitalized costs are amortized based on current and future revenue for each product with minimum annual amortization equal to the straight-line amortization over the estimated economic life of the product. The Company is amortizing capitalized costs on a straight-line basis over five years. During 1999, 1998, and 1997, the Company capitalized \$30,192,000, \$25,052,000, and \$18,373,000, respectively, of total software development costs of \$88,699,000, \$74,159,000, and \$54,524,000, respectively. Amortization expense of capitalized software development costs in 1999, 1998, and 1997 was \$14,156,000, \$10,647,000, and \$7,935,000, respectively, and accumulated amortization was \$57,698,000, \$43,542,000, and \$32,895,000, respectively.

(e) **Cash Equivalents** - Cash equivalents consist of short-term marketable securities with original maturities less than ninety days.

(f) **Investments** - The Company accounts for its investments in equity securities which have readily determinable fair values as available-for-sale. Available-for-sale securities are reported at fair value with unrealized gains and losses reported, net of tax, as a separate component of accumulated other comprehensive income. Investments in the common stock of certain affiliates over which the Company exerts significant influence are accounted for by the equity method. Investments in other equity securities are reported at cost. All equity securities are reviewed by the Company for declines in fair value. If such declines are considered to be other than temporary, the cost basis of the individual security is written down to fair value as a new cost basis, and the amount of the write-down is included in earnings.

(g) **Inventory** - Inventory consists primarily of computer hardware held for resale and is recorded at the lower of cost (first-in, first-out) or market.

## Notes to Consolidated Financial Statements

(h) **Property and Equipment** - Property, equipment, and leasehold improvements are stated at cost. Depreciation of property and equipment is computed using the straight-line method over periods of 5 to 39 years. Amortization of leasehold improvements is computed using a straight-line method over the lease terms, which range from periods of two to twelve years.

(i) **Earnings per Common Share** - Basic earnings per share (EPS) excludes dilution and is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company. A reconciliation of the numerators and the denominators of the basic and diluted per-share computations is as follows:

(In thousands, except per share data)

	1999			1998			1997		
	Earnings (Numerator)	Shares (Denominator)	Per-Share Amount	Earnings (Numerator)	Shares (Denominator)	Per-Share Amount	Earnings (Numerator)	Shares (Denominator)	Per-Share Amount
<u>Earnings per share before extraordinary item</u>									
Basic earnings per share									
Income available to common stockholders	\$ 184	33,623	<u>\$ .01</u>	20,589	32,825	<u>\$ .63</u>	15,148	32,881	<u>\$ .46</u>
Effect of dilutive securities									
Stock options	—	293		—	842		—	787	
Diluted earnings per share									
Income available to common stockholders including assumed conversions	<u>\$ 184</u>	<u>33,916</u>	<u>\$ .01</u>	<u>20,589</u>	<u>33,667</u>	<u>\$ .61</u>	<u>15,148</u>	<u>33,668</u>	<u>\$ .45</u>
<u>Net earnings (loss) per share</u>									
Basic earnings (loss) per share									
Income available to common stockholders	\$ (1,211)	33,623	<u>\$(.04)</u>	20,589	32,825	<u>\$ .63</u>	15,148	32,881	<u>\$ .46</u>
Effect of dilutive securities									
Stock options	—	293		—	842		—	787	
Diluted earnings (loss) per share									
Income available to common stockholders including assumed conversions	<u>\$ (1,211)</u>	<u>33,916</u>	<u>\$(.04)</u>	<u>20,589</u>	<u>33,667</u>	<u>\$ .61</u>	<u>15,148</u>	<u>33,668</u>	<u>\$ .45</u>

Options to purchase 3,185,000, 1,652,000 and 1,149,000 shares of common stock at per share prices ranging from \$17.50 to \$31.00, \$25.00 to \$31.00, and \$21.50 to \$31.00 were outstanding at the end of 1999, 1998 and 1997, respectively, but were not included in the computation of diluted earnings per share because the options' exercise price was greater than the average market price of the common shares.

## Notes to Consolidated Financial Statements

---

(j) **Foreign Currency** - Assets and liabilities in foreign currencies are translated into dollars at rates prevailing at the balance sheet date. Revenues and expenses are translated at average rates for the year. The net exchange differences resulting from these translations are reported in accumulated other comprehensive income. Gains and losses resulting from foreign currency transactions are included in the consolidated statements of earnings. The net gain (loss) resulting from foreign currency transactions was \$95,000, (\$673,000), and (\$762,000) in 1999, 1998, and 1997, respectively.

(k) **Income Taxes** - Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

(l) **Goodwill** - Excess of cost over net assets acquired (goodwill) is being amortized on a straight-line basis over seven to eight years. Accumulated amortization was \$5,387,000 and \$4,037,000 at the end of 1999 and 1998, respectively. The Company assesses the recoverability of goodwill based on forecasted undiscounted future operating cash flows.

(m) **Use of Estimates** - The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

## 2 Acquisition of Business

On March 16, 1998, the Company purchased all of the outstanding common stock of Multum Information Systems, Inc., (Multum) for \$6.9 million. Multum is a supplier to the healthcare industry of drug knowledge databases and intelligent software components designed to improve the quality and cost-effectiveness of medical care. The Company plans to incorporate Multum's drug information and expert dosing component into its Health Network Architecture Millennium solutions to enable Multum's expert knowledge to become executable within the process of care delivery.

The acquisition has been accounted for using the purchase method of accounting with the operating results of Multum included in the Company's consolidated statement of earnings since the date of acquisition. Approximately \$5,000,000 of the purchase price was allocated to in-process research and development that had not reached technological feasibility and was treated as a one-time charge to earnings reducing after tax income for 1998 by \$3.1 million or \$.09 per share on a diluted basis. This acquisition would not have materially affected revenues, net earnings, or earnings per share on a pro forma basis for any period presented.

The acquired in-process research and development related to Multum's component based, drug information software development kit (SDK) for use in clinical information systems. Its components are designed for use in a variety of configurations and to provide complete control over the retrieval of drug information from Multum's knowledge databases. SDK was approximately 80% complete at the time of the acquisition. When Multum was acquired, it was projected that SDK would be completed in 12-18 months at an estimated cost of \$1.9 million. The risks associated with completing SDK are like any other software development project and include changes in technology and competition. The SDK project was valued using the income approach with the following assumptions: material net cash inflows are expected to commence in 2000; no material changes from historical pricing, margins or expense levels are anticipated; and, a 20% risk adjusted discount rate was applied to estimated net cash flows. SDK was approximately 90% complete at the end of 1998 and was completed in 1999.

The allocation of the purchase price to the estimated fair values of the identified tangible and intangible assets acquired and liabilities assumed, resulted in goodwill of \$1,581,000. The goodwill is being amortized straight-line over seven years.

## Notes to Consolidated Financial Statements

---

### 3 Receivables

Receivables consist of accounts receivable and contracts receivable. Accounts receivable represent recorded revenues that have been billed. Contracts receivable represent recorded revenues that are billable by the Company at future dates under the terms of a contract with a client. Billings and other consideration received on contracts in excess of related revenues recognized under the percentage-of-completion method are recorded as deferred revenue. A summary of receivables is as follows:

(In thousands)	<u>1999</u>	<u>1998</u>
Accounts receivable	\$ 85,814	72,747
Contracts receivable	<u>75,360</u>	<u>94,627</u>
Total receivables	<u>\$ 161,174</u>	<u>167,374</u>

Substantially all receivables are derived from sales and related support and maintenance of the Company's clinical information systems to healthcare providers located throughout the United States and in certain foreign countries. Included in receivables at the end of 1999 and 1998 are amounts due from healthcare providers located in foreign countries of \$17,704,000 and \$12,071,000, respectively. Consolidated revenues include foreign sales of \$24,001,000, \$17,545,000, and \$16,272,000, during 1999, 1998, and 1997, respectively. Consolidated long-lived assets at the end of 1999 and 1998, include foreign long-lived assets of \$638,000 and \$290,000, respectively. Revenues and long-lived assets from any one foreign country are not material.

The Company provides an allowance for estimated uncollectible accounts based upon historical experience and management's judgment. At the end of 1999 and 1998 the allowance for estimated uncollectible accounts was \$4,759,000 and \$3,405,000, respectively.

### 4 Property and Equipment

A summary of property, equipment, and leasehold improvements stated at cost, less accumulated depreciation and amortization, is as follows:

(In thousands)	<u>1999</u>	<u>1998</u>
Furniture and fixtures	\$ 21,623	19,153
Computer and communications equipment	67,462	59,280
Marketing equipment	1,984	1,913
Leasehold improvements	16,905	13,543
Capital lease equipment	713	713
Land, buildings, and improvements	<u>32,437</u>	<u>32,437</u>
	141,124	127,039
Less accumulated depreciation and amortization	<u>63,186</u>	<u>49,747</u>
Total property and equipment, net	<u>\$ 77,938</u>	<u>77,292</u>



## Notes to Consolidated Financial Statements

### 5 Investments

Investments consist of the following:

(In thousands)	1999	1998
Investments in available-for-sale equity securities	\$ 13,057	503
Plus unrealized holding gain (loss)	166,781	(431)
Investment in available-for-sale equity securities, at fair value	179,838	72
Investments in equity securities, at cost	69,822	70,000
Investments accounted for under the equity method	2,463	1,647
Total investments, net	\$ 252,123	71,719

Included in the Company's investments is the ownership of 13,149,259 shares (18.7%) of common stock, of CareInsite, Inc. ("CareInsite"), formerly known as Syntec Healthcare Communications, Inc. which have a cost basis of \$81,804,000 and a carrying value of \$248,821,000 at January 1, 2000. 12,437,500 of these shares were received in 1998 as consideration for the sale of license software, and an additional 711,759 shares were purchased in 1999. The value assigned to the shares acquired in 1998 was \$70,000,000 and was based on a methodology which utilized both a comparable company and the expected underlying discounted future cash flows. On June 16, 1999, CareInsite undertook an initial public offering of common stock. The common stock of CareInsite is traded in the public market and listed on the Nasdaq National Market. The stock of CareInsite held by the Company is not registered and is subject to certain lock-up provisions. A permanent impairment in the value of CareInsite common stock would result in a charge to earnings in either the then current or future periods. There would be no effect on cash flows because the revenue was earned through contractual rights granted in exchange for CareInsite stock. An increase in the value of the CareInsite stock would have no effect on reported earnings. The Company has not engaged in equity swaps or other hedging techniques to manage the equity risk inherent in the CareInsite shares.

Under Statement of Financial Accounting Standards no. 115 "Accounting for Certain Investments in Debt and Equity Securities" (SFAS No. 115), the Company is required to mark to market those shares which are classified as available-for-sale. Additionally, SFAS No. 115 requires shares that are eligible under Rule 144 for public sale within a twelve month period be considered as available-for-sale. Under Rule 144, as currently in effect, a person who has beneficially owned shares of common stock for at least one year would be entitled to sell within any three-month period a number of shares that does not exceed the greater of 1% of the number of shares of common stock then outstanding and the average weekly trading volume of the common stock during the four preceding calendar weeks. As of January 1, 2000, the Company has marked to market 2,230,700 shares of CareInsite common stock, with a market value of \$179,571,000, that are considered available-for-sale under Rule 144 and SFAS No.115. All CareInsite shares the Company owns will be considered available-for-sale and be marked to market in the first quarter of 2000. If all shares were eligible to be marked to market at January 1, 2000, the market value would be \$1,058,515,000.

If the Company realizes certain performance metrics related to specified levels of physician usage, CareInsite will issue to the Company 2,503,125 shares of common stock at a price of \$.01 per share ("Performance Shares"). The measurement date is February 15, 2001. No amounts have been recognized in the consolidated financial statements for the Performance Shares due to the uncertainty of the future events.

The Company was also granted, by CareInsite, 1,008,445 common stock warrants with an exercise price of \$4.00 per share ("THINC Warrants"). The THINC Warrants were exercisable only in the event that The Health Information Network Connections, LLC ("THINC") exercised warrants granted to them by CareInsite at \$4.00 per share. THINC was allowed to exercise their warrants 180 days after the initial public offering of CareInsite. On January 29, 2000 CareInsite completed an acquisition of THINC. As part of that agreement, 806,756 of the 1,008,445 THINC Warrants became immediately exercisable, with the remaining amount forfeited. The THINC Warrants expire in three years.

On February 13, 2000 CareInsite entered into an agreement to merge with Healtheon/WebMD Corporation ("Merger Agreement"). As part of the Merger Agreement, the Company will receive 1.3 shares of Healtheon/WebMD Corporation in exchange for each common share of CareInsite held by the Company. In addition the Performance Shares will be adjusted at a rate of 1.3 shares of Healtheon/WebMD Corporation for each share of CareInsite. All physician users of systems of Healtheon/WebMD Corporation or its affiliates shall be included for purposes of determining the specified levels of physician usage. The THINC Warrants will also be adjusted at a rate of 1.3 shares of Healtheon/WebMD Corporation for each share of CareInsite. The proposed merger of CareInsite and Healtheon/WebMD Corporation ("Merger") is subject to shareholder and regulatory approval. There is no guarantee the Merger will close.

## Notes to Consolidated Financial Statements

The Company has agreed under terms of the Merger Agreement to certain lock-up provisions, which differ from the terms of its lock-up provisions with CareInsite. The Merger is expected to close in the second quarter of 2000. If the Merger closes the Company will record the Healtheon/WebMD Corporation shares received at their then fair value and recognize a gain on the disposition of the CareInsite shares. Based on proposed lock-up provisions, 50% of the Healtheon/WebMD Corporation shares would thereafter be considered available-for-sale and would be marked to market at each balance sheet date. The remainder would be carried at cost until the third quarter of 2000.

The Company owns 50% of Health Network Ventures ("HNV"), a joint venture investment which is accounted for under the equity method. Under the terms of the joint venture agreement, the Company may require its partner to sell to the Company its share of HNV for \$12,000,000, subject to certain adjustments, ("Call Option") at anytime after July 1, 2000. In addition the partner may require the Company to purchase its share of HNV for \$6,000,000, subject to certain adjustments, ("Put Option") at any time after July 1, 2000.

### 6 Indebtedness

The Company has a loan agreement with a bank that provides for a long-term revolving line of credit for working capital purposes. The long-term revolving line of credit is unsecured and requires monthly payments of interest only. Interest is payable at the Company's option at a rate based on prime (8.5% at January 1, 2000) or LIBOR (6.5% at January 1, 2000) plus 1.5%. The interest rate may be reduced by up to .4% if certain net worth ratios are maintained. At January 1, 2000, the Company had no outstanding borrowings under this agreement and had \$18,000,000 available for working capital purposes. The agreement contains certain net worth, current ratio, and fixed charge coverage covenants and provides certain restrictions on the Company's ability to borrow, incur liens, sell assets, and pay dividends. A commitment fee of 3/10% is payable quarterly on the unused portion of the revolving line of credit.

On April 15, 1999, the Company completed a \$100,000,000 private placement of debt pursuant to a Note Agreement dated April 1, 1999. The Series A Senior Notes, with a \$60,000,000 principal amount at 7.14% are payable in five equal annual installments beginning in April 2002. The Series B Senior Notes, with a \$40,000,000 principal amount at 7.66% are payable in six equal annual installments beginning April 2004. The proceeds were used to retire the Company's existing \$30,000,000 of debt, and the remaining funds will be used for proposed capital improvements and to strengthen the Company's cash position. In connection with the early extinguishment of debt, the Company incurred an extraordinary loss for a prepayment penalty and write-off of deferred loan costs of \$1,395,000 net of taxes. The note agreement contains certain net worth, current ratio, and fixed charge coverage covenants and provides certain restrictions on the Company's ability to borrow, incur liens, sell assets, and pay dividends. The Company was in compliance with all covenants at January 1, 2000.

The fair value of the Company's Senior Notes approximates their carrying value at January 1, 2000 based on current rates offered to the Company for similar debt instruments of comparable maturities.

### 7 Interest Income and Expense

A summary of interest income and expense is as follows:

(In thousands)	1999	1998	1997
Interest income	\$ 2,582	2,242	4,755
Interest expense	(5,978)	(2,504)	(2,441)
Interest income (expense), net	\$ (3,396)	(262)	2,314

### 8 Stock Options and Warrants

At January 1, 2000, the Company had four fixed stock option plans. Under Stock Option Plan B, the Company could grant to associates options to purchase up to 5,600,000 shares of common stock through November 30, 1993. The options are exercisable at the fair market value on the date of grant for a period determined by the Board of Directors (not more than ten years from the date granted). The options contain restrictions as to transferability and exercisability after termination of employment.

Under Stock Option Plan C, the Company is authorized to grant to associates options to purchase up to 95,000 shares of common stock through May 18, 2003. The options are exercisable at the fair market value on the date of grant for a period determined by the Board of Directors (not more than ten years from the date granted). The options contain restrictions as to transferability and exercisability after termination of employment. The Company has committed not to issue any more stock options under Stock Option Plan C.

## Notes to Consolidated Financial Statements

Initially under Stock Option Plan D, the Company was authorized to grant to associates, directors, consultants, or advisors to the Company options to purchase up to 2,600,000 shares of common stock through January 1, 2005. An additional 2,000,000 shares were approved by the Company's shareholders on May 22, 1998, increasing the total authorized to grant to 4,600,000 shares. The options are exercisable at a price (not less than fair market value on the date of grant) and during a period determined by the Stock Option Committee. Options under this plan currently vest over periods of up to ten years and are exercisable for periods of up to 25 years.

Under Stock Option Plan E, the Company is authorized to grant to associates (other than officers subject to the provisions of Section 16(a) of the Securities and Exchange Act of 1934), consultants, or advisors to the Company options to purchase up to 2,000,000 shares of common stock through January 1, 2005. The options are exercisable at a price (not less than fair market value on the date of grant) and during a period determined by the Stock Option Committee. Options under this plan currently vest over periods of up to ten years and are exercisable for periods of up to 25 years.

The Company has also granted 210,362 other non-qualified stock options under separate agreements to certain third parties. These options are exercisable at a price equal to or greater than the fair market value on the date of grant. These options vest over periods of up to six years and are exercisable for periods of up to ten years.

The Company accounts for stock options in accordance with the provisions of Accounting Principles Board (APB) Opinion No. 25, "Accounting for Stock Issued to Employees", and related interpretations. As such, compensation expense is recorded on the date of grant only if the current market price of the underlying stock exceeds the exercise price. On December 31, 1995, the Company adopted Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based Compensation" (FAS 123), which permits entities to recognize as expense over the vesting period the fair value of all stock-based awards on the date of grant. Alternatively, FAS 123 allows entities to continue to apply the provisions of APB Opinion No. 25 and provide pro forma net earnings and pro forma earnings per share disclosures for employee stock option grants made in 1995 and future years as if the fair-value-based method defined in FAS 123 had been applied. The Company has elected to continue to apply the provisions of APB Opinion No. 25 and provide the pro forma disclosure provisions of FAS 123.

A combined summary of the status of the Company's four fixed stock option plans and other stock options at the end of 1999, 1998, and 1997, and changes during these years ended is presented below:

	1999		1998		1997	
	Number of shares	Weighted-average exercise price	Number of Shares	Weighted-average exercise price	Number of shares	Weighted-average exercise price
<b>Fixed options</b>						
Outstanding at beginning of year	5,488,191	\$ 20.38	4,179,258	\$ 17.74	3,196,072	\$ 16.50
Granted	1,447,246	16.69	1,932,710	24.15	1,592,363	18.22
Exercised	(255,747)	4.91	(185,335)	6.88	(310,531)	3.12
Forfeited	(1,149,695)	22.40	(438,442)	17.57	(298,646)	17.50
Outstanding at end of year	<u>5,529,995</u>	\$ 19.79	<u>5,488,191</u>	\$ 20.38	<u>4,179,258</u>	\$ 17.74
Options exercisable at year-end	1,297,147		1,111,943		876,376	

The following table summarizes information about fixed and other stock options outstanding at January 1, 2000.

Options outstanding				Options exercisable	
Range of exercise prices	Number Outstanding At 01/01/00	Weighted-average Remaining contractual life	Weighted-average exercise price	Number exercisable at 01/01/00	Weighted-average exercise price
\$ 1.34-15.00	1,762,957	17.8 years	\$ 14.03	494,770	\$ 13.06
15.13-20.50	1,393,497	13.5	17.71	305,613	18.51
20.56-25.00	1,411,870	12.4	23.19	205,557	22.97
25.88-31.00	<u>961,671</u>	14.8	28.37	<u>291,207</u>	29.01
1.34-31.00	<u>5,529,995</u>	14.8	19.79	<u>1,297,147</u>	19.49

## Notes to Consolidated Financial Statements

The per share weighted-average fair value of stock options granted during 1999, 1998 and 1997 was \$10.88, \$14.97 and \$10.99, respectively, on the date of grant using the Black Scholes option-pricing model with the following weighted-average assumptions:

	1999	1998	1997
Expected years until exercise	8	8	8
Risk-free interest rate	6.9%	5.0%	6.2%
Expected stock volatility	61.3%	58.5%	56.9%
Expected dividend yield	0%	0%	0%

Since the Company applies APB Opinion No. 25 in accounting for its plans, no compensation cost has been recognized for its stock options issued to employees. Had the Company recorded compensation expense based on the fair value at the grant date for its stock options under FAS 123, the Company's net earnings and earnings per share on a diluted basis would have been reduced by approximately \$3,922,000 or \$.12 per share in 1999, approximately \$5,929,000 or \$.18 per share in 1998 and approximately \$3,965,000 or \$.12 per share in 1997.

Pro forma net earnings reflect only options granted since January 1, 1995. Therefore, the full impact of calculating compensation expense for stock options under FAS 123 is not reflected in the pro forma net earnings amounts presented above, because compensation cost is reflected over the options' vesting period of ten years for these options. Compensation expense for options granted prior to January 1, 1995 is not considered.

In November 1998, the Company entered into an agreement with General Electric Company (GE) to integrate the Company's Health Network Architecture Millennium RadNet Radiology Information System with GE Medical Systems' Picture Archive and Communication Systems technology. In conjunction with the agreement, the Company sold GE 670,000 shares of common stock for \$14,874,000 and granted warrants for the purchase of 500,000 shares of common stock at an exercise price equal to the fair value of the stock at the grant date (\$25.49). The warrants become exercisable provided certain conditions are met, including achievement of certain levels of revenue. The warrants expire after seven years or thirty days after termination of the agreement.

## 9 Income Taxes

Income tax expense (benefit) before extraordinary item for the years ended 1999, 1998, and 1997, consists of the following:

(In thousands)	1999	1998	1997
Current:			
Federal	\$ 3,514	(1,929)	916
State	573	(1,061)	80
Foreign	(804)	(147)	94
Total current	<u>3,283</u>	<u>(3,137)</u>	<u>1,090</u>
Deferred:			
Federal	(2,891)	13,634	7,338
State	(288)	1,565	908
Foreign	14	617	-
Total deferred	<u>(3,165)</u>	<u>15,816</u>	<u>8,246</u>
Total income tax expense	\$ <u>118</u>	<u>12,679</u>	<u>9,336</u>

Income tax benefit attributable to the extraordinary item (early retirement of debt) was \$865,000 in 1999. Income tax expense (benefit) allocated to stockholders' equity for unrealized holding gain (losses) on available-for-sale equity securities was \$59,971,000 and (\$165,000) in 1999 and 1998, respectively.

## Notes to Consolidated Financial Statements

Temporary differences between the financial statement carrying amounts and tax bases of assets and liabilities that give rise to significant portions of deferred income taxes at the end of 1999 and 1998 relate to the following:

(In thousands)	1999	1998
Deferred Tax Assets		
Contract reserves	\$ 3,615	-
Acquisition accrual	1,779	2,033
Accrued expenses	4,669	3,223
Separate return net operating losses	-	1,577
Other	1,637	1,076
Total deferred tax assets	<u>11,700</u>	<u>7,909</u>
Deferred Tax Liabilities		
Unrealized gain on investments	(59,806)	-
Software development costs	(26,812)	(20,695)
Contract and service revenues and costs	(23,591)	(32,255)
Depreciation and amortization	(4,480)	(3,856)
Other	(5,581)	(2,867)
Total deferred tax liabilities	<u>(120,270)</u>	<u>(59,673)</u>
Net deferred tax liability	\$ <u>(108,570)</u>	<u>(51,764)</u>

The effective income tax rates for 1999, 1998, and 1997 were 39%, 38%, and 38%, respectively. These effective rates differ from the federal statutory rate of 35% as follows:

(In thousands)	1999	1998	1997
Tax expense at statutory rates	\$ 106	11,644	8,569
State income tax, net of federal benefit	10	1,280	632
Other, net	2	(245)	135
Total income tax expense	\$ <u>118</u>	<u>12,679</u>	<u>9,336</u>

Income taxes payable are reduced by the tax benefit resulting from disqualifying dispositions of stock acquired under the Company's stock option plans. The 1999, 1998, and 1997 benefits of \$594,000, \$621,000, and \$521,000, respectively, are treated as increases to additional paid-in capital.

### 10 Foundations Retirement Plan

The Cerner Corporation Foundations Retirement Plan (the Plan) is established under Section 401(k) of the Internal Revenue Code. All full-time associates are eligible to participate. Participants may elect to make pretax contributions from 1% to 15% of compensation to the Plan, subject to annual limitations determined by the Internal Revenue Service. Participants may direct contributions into mutual funds, a money market fund, or a Company stock fund. The Company makes matching contributions to the Plan, on behalf of participants, in an amount equal to 20% of the participant's contribution, limited to an annual maximum of \$600 per participant. The Company's expense for the plan amounted to \$1,187,000, \$1,005,000, and \$761,000 for 1999, 1998, and 1997, respectively.

## Notes to Consolidated Financial Statements

---

### 11 Related Party Transactions

In 1999, the Company loaned \$3,628,000 to the Company's senior management under the terms of the Executive Stock Purchase Program ("Program"). The purpose of the Program is to advance the interests of the Company, the Company's senior management, and the Company's shareholders by offering the Company's senior management an incentive to purchase shares of the Company's stock on the open market. Pursuant to the Program, the Company provided Program loans to executives to help finance up to 50% of the total purchase price of the stock purchased. All Program loans have a term of five (5) years, at an interest rate of 5.5%. Principal and interest is not due until the end of the five-year loan term, unless the executive terminates employment. Executives may also elect to pay interest annually. If interest is not paid annually, it will compound annually. All Program loans are secured by the purchased shares and any pledged shares.

### 12 Commitments

The Company leases space to unrelated parties in its Kansas City headquarters complex under noncancelable operating leases. Included in other revenues is rental income of \$1,005,000, \$1,795,000, and \$1,694,000 in 1999, 1998, and 1997, respectively.

The Company is committed under operating leases for office space through December 2004. Rent expense for office and warehouse space for the Company's regional and international offices for 1999, 1998, and 1997 was \$2,226,000, \$1,847,000, and \$1,759,000, respectively. Future minimum lease revenues (in thousands) and aggregate minimum future payments (in thousands) under these noncancelable operating leases are as follows:

Years	Future Minimum lease revenues	Future Minimum lease commitments
2000	\$ 425	1,566
2001	176	719
2002	40	428
2003	23	435
2004	-	267

In December, 1999, the Company made a decision to close five of its branch offices. The Company created a regional branch structure in 1994 in order to bring associates closer to its clients. The natural evolution of that strategy and the ability to leverage internal information technology infrastructure to create a more virtual workplace has resulted in a significant decrease in utilization of certain regional offices. This led to the decision to close these physical locations. The Company recorded a charge of \$1.4 million in sales and client service expenses in the 1999 fourth quarter to provide for the costs of closing these locations, primarily based on estimated lease cancellation fees. The Company will continue to maintain offices in Denver, Detroit and Australia, in addition to the world headquarters in Kansas City, Missouri.

### 13 Stockholders' Equity

At the end of 1999 and 1998, the Company had 1,000,000 shares of authorized but unissued preferred stock, \$.01 par value.

## Notes to Consolidated Financial Statements

### 14 Quarterly Results (unaudited)

Selected quarterly financial data for 1999 and 1998 is set forth below:

(In thousands, except per share data)

		Revenues	Earnings (loss) before income taxes and extraordinary item	Net earnings (loss)	Basic earnings (loss) per share	Diluted earnings (loss) per share
1999 quarterly results:						
April 3	\$	86,743	4,543	2,817	.08	.08
July 3 (1)		82,782	428	(1,135)	(.03)	(.03)
October 2		80,929	1,146	680	.02	.02
January 1 (2)		89,743	(5,815)	(3,573)	(.11)	(.11)
Total	\$	<u>340,197</u>	<u>302</u>	<u>(1,211)</u>	<u>(.04)</u>	<u>(.04)</u>
1998 quarterly results:						
April 4 (3)	\$	73,674	1,106	671	.02	.02
July 4		79,152	8,726	5,369	.16	.16
October 3		82,832	10,185	6,348	.19	.19
January 2		95,244	13,251	8,201	.26	.24
Total	\$	<u>330,902</u>	<u>33,268</u>	<u>20,589</u>	<u>.63</u>	<u>.61</u>

(1) In the second quarter of 1999, the Company incurred an extraordinary loss on the early extinguishment of debt of \$1,395,000, net of taxes of \$865,000. Earnings, basic earnings per share, and diluted earnings per share, before the extraordinary item for the second quarter of 1999 were \$260,000, \$0.01, and \$0.01, respectively.

(2) See note 12 regarding a non-recurring charge in the fourth quarter of 1999. The fourth quarter of 1999 also includes an additional non-recurring charge of \$5.8 million, net of \$3.6 million tax benefit, for contract reserves.

(3) See note 2 regarding a non-recurring charge in the first quarter of 1998.

In lieu of a traditional annual report for 1999, CERNER CORPORATION is pleased to issue this enhanced version of our Form 10K as filed with the Securities and Exchange Commission. This format change saves \$100,000 compared to the costs incurred with the production of a traditional annual report. In today's digital world, we believe these funds are better invested in Cerner's corporate web site, which serves as a significant resource for clients, investors and other constituencies. Please visit our site at [www.cerner.com](http://www.cerner.com).

CERNER



## CERNER LEADERSHIP AND CORPORATE INFORMATION

---

### BOARD OF DIRECTORS

---

**Neal L. Patterson**  
Chairman of the Board  
& Chief Executive Officer  
Cerner Corporation

**Clifford W. Illig**  
Vice Chairman  
Cerner Corporation

**Gerald E. Bisbee Jr., Ph.D.**  
Chairman &  
Chief Executive Officer  
ReGen Biologics Inc.  
Redwood City, CA

**John C. Danforth**  
Partner  
Bryan Cave LLP  
St. Louis, MO

**Jeff C. Goldsmith, Ph.D.**  
President  
Health Futures, Inc.  
Charlottesville, VA

**Michael E. Herman**  
President, Kansas City Royals  
Baseball Club  
Kansas City, MO

**Thomas C. Tinstman, M.D.**  
Senior Vice President &  
Chief Medical Officer  
Cerner Corporation

### Annual Meeting of Shareholders

The annual meeting will be held at 10:00 a.m. on May 26, 2000, at the Cerner Associate Center, located on the Cerner campus at 2901 Rockcreek Parkway, Kansas City, Missouri. A formal notice of the meeting, with a proxy statement and proxy form, will be mailed to each shareholder in April 2000.

### Annual Report/10-K Report

Publications of interest to current and potential Cerner investors are available upon written request or via Cerner's Web site at [www.cerner.com](http://www.cerner.com). These include annual and quarterly reports and the Form 10-K filed with the Securities and Exchange Commission.

Such requests should be made to:

Administrator of  
Shareholder Relations  
Cerner Corporation  
2800 Rockcreek Parkway  
Kansas City, MO  
64117-2551

Inquiries of an administrative nature relating to shareholder accounting records, stock transfer, change of address, and miscellaneous shareholder requests should be directed to the transfer agent and registrar, UMB Bank, at (816) 860-7786.

### Transfer Agent and Registrar

Securities Transfer Division  
UMB Bank  
P.O. Box 410064  
Kansas City, MO 64141-0064  
(816) 860 7786

### Stock Listings

Cerner Corporation's common stock trades on The Nasdaq Stock Market<sup>SM</sup> under the symbol CERN.

### Independent Accountants

KPMG LLP  
Kansas City, MO

### Legal Counsel

Stinson, Mag & Fizzell  
Kansas City, MO

### MANAGEMENT

---

#### Executive Officers & Corporate Management

**Neal L. Patterson**  
Chairman of the Board  
& Chief Executive Officer

**Clifford W. Illig**  
Vice Chairman

**Earl H. Devanny, III**  
President

**Glenn P. Tobin, Ph.D.**  
Executive Vice President &  
Chief Operating Officer

**Marc G. Naughton**  
Vice President &  
Chief Financial Officer

**Jack A. Newman Jr.**  
Executive Vice President

**Stanley M. Sword**  
Vice President & Chief People  
Officer

**Randy D. Sims**  
Vice President, Chief Legal Officer  
& Secretary

**Thomas C. Tinstman, M.D.**  
Senior Vice President &  
Chief Medical Officer

#### Client Organization

**Paul M. Black**  
Senior Vice President &  
Chief Sales Officer

**Richard J. Flanigan Jr.**  
Senior Vice President &  
General Manager

#### Cerner Consulting

**Stephen D. Garver**  
Senior Vice President  
& Managing Partner

**Paul J. Sinclair**  
Vice President, Senior Partner &  
North American Operations Officer

**Robert J. Campbell**  
Vice President of Learning

#### Client Services Organization

**Stephen M. Goodrich**  
Senior Vice President

#### Product Organization

**Jeffrey A. Townsend**  
Vice President &  
Chief Engineering Officer

**David P. McCallie Jr., M.D.**  
Vice President Medical  
Informatics & Chief Scientist

#### International Organization

**Douglas M. Krebs**  
President  
Cerner International

## ENTERPRISE SOLUTIONS

### CapStone™

Health organizations solutions for creating enterprisewide master person identification (EMPI), referrals, registration, and scheduling; and health plan member eligibility and coverage information

### PowerChart™

The electronic medical record, including charts, flowsheets, ordering, and clinical documentation

### ePowerChart

The Internet web-enabled version of PowerChart

### PowerLink™

Connection solutions for connecting physicians to payers and health systems for referrals, authorization, claims, eligibility, clinical information, and reporting

### PowerVision

Manager's desktop for managerial business information and decision support

## ENTERPRISE REPOSITORIES

### Open Person Foundation™

Open, person-centric EMPI repository for enterprisewide person/patient identification and reconciliation that creates the foundation for integrating the person throughout all clinical and financial systems. A component of CapStone

### Open Clinical Foundation®

Open repository to manage clinical information providing the foundation for the electronic medical record. Sold as a component of PowerChart

### Open Management Foundation™

Open repository to store management information of enterprise financial, operational and process results, creating the foundation for the enterprisewide management and executive information system

### Open Outcomes Foundation™

Open repository to store clinical, medical, process, economic, and satisfaction outcomes results creating the foundation for an enterprisewide outcomes management system

### Open Agreement Foundation™

Open repository to manage health plan contracts and agreements, and member information

## CLINICAL SOLUTIONS

### Patient Care Systems

#### CareNet®

Care team workflow automation that includes task management, order entry, clinical documentation, care planning and coordination, and chart viewing

#### INet™

Automated clinical information system for intensive and critical care units with high levels of real-time patient monitoring equipment

#### ProVide™

Physician office workflow management systems for clinical, business, and support needs, including electronic medical records, care plans, registration, orders, clinical documentation, scheduling, and billing

#### eProVide™

Web-enabled version of ProVide with expanded Internet functionality

#### ProCall®

Home care workflow and management system that seamlessly integrates clinical and financial information from all venues of home care while meeting stringent regulatory requirements

## CLINICAL INFORMATION SYSTEMS for CARE RESOURCE CENTERS

#### FirstNet™

Emergency care information system that provides customized and automated patient and provider tracking, patient and medical assessment charting, and clinical and management reporting

#### CVNet™

Clinical cardiology information system that automates and integrates clinical and business processes

#### SurgiNet®

Surgery information system that enables booking of multiple resources, checking scheduling conflicts, and patient scheduling

#### PathNet®

Laboratory information system that automates the clinical and management processes of the entire laboratory including microbiology, anatomic pathology, HLA, blood bank services, outreach services, and lab management

#### RadNet®

Clinical radiology information system that automates departmental operations including patient registration, order entry, exam tracking, film tracking, transcription, electronic signatures, and report distribution

#### PharmNet®

Clinical pharmacy information system that automates the medication process across the continuum of care

## IMAGE MANAGEMENT SYSTEMS

#### ProView™

Clinical image viewer and document management system

#### Cerner Document Imaging

Integrated enterprise document storage and management

## FINANCIAL, OPERATIONAL, and MANAGEMENT SYSTEMS

#### ProFit™

Enterprise billing and accounts receivable system

#### ProFile™

Health information management department system for medical records storage, tracking, and accessing

#### ProCost™

Enterprise cost management, including cost analysis, cost accounting, variance tracking and integration with overall decision support solutions

#### ProForm™

Enterprise financial/operational decision support for performance profiling, productivity analysis, and executive key indicator dashboard

#### ProCure™

Automated materials management system integrated into the clinical processes

### Managed Care Systems

#### ProTrack™

Automated equipment management system integrated into the clinical processes Managed Care Systems

#### ProCare™

Enterprise decision support for medical management, including performance profiling of providers, clinics, and hospitals

#### ProRate™

Managed care system for membership and eligibility tracking, claims processing, and contract management

## KNOWLEDGE SOLUTIONS

---

### Clinical Decision Support Systems

---

#### PowerNote™

Automates the creation of clinical documentation using Care Designs across the various care settings within an integrated or disparate health system

#### Discern Expert®

Built-in expert rule-based event monitor to perform clinical and management. Alerts and real-time, interactive guidelines and reminders

#### Discern Explorer®

Versatile tool for performing ad hoc or predefined queries and reports against the *HNA Millennium* data model

### Executable Knowledge, Knowledge Bases and Content

---

#### Cerner Multum

Integrates comprehensive drug information with information technology to provide person-centric clinical, drug utilization review, and clinical decision support

#### Care Designs™

Domain-specific encounter pathways that support real-time structured clinical documentation, assessments, and plans of care

#### Alerts™

Automated clinical guidelines that provide decision support.

#### Cerner Knowledge Index™

A standard and flexible data dictionary used to assign unique identifiers to, and map and express the relationships between, the following types of reference content: clinical concepts, terms, medications, diagnostic and treatment procedures, and billing and diagnosis classification schemes

#### Insights™

Real-time, actionable alerts that present patient-specific and situation-specific information

#### Health Facts™

Comparative data for benchmarking and process improvement

## eHEALTH SOLUTIONS

---

### Personal Health Systems

---

#### Surveys and Assessments

Personal health assessments and interventions to promote self-care and health maintenance

#### ProLink™

Call center system for triage and disease management centers that assists with demand management, patient education, medication and treatment plan compliance monitoring, and physician office answering and scheduling services

#### Personal Health Record

Personal health management software to access and maintain health records, wellness plans, and information

### Internet-Based Systems

---

#### Vitality.com

Internet-based system for Vitality

#### IQRx

Medication information and services for physicians, pharmacists, and consumers

#### IQHealth.com

Consumer and physician portal to health and medical information and services

#### Cerner Health

Connections™  
Compliance management and triage telecare services

## SYSTEM INTEGRATION SOLUTIONS

---

### Interface Technologies

---

#### Open Engine Application

Gateway System™  
Foreign system interface and communication services

#### Open Port Interface

System™  
Foreign system and medical device interfaces

## CERNER CONSULTING SERVICES

---

#### Implementation Services

Provides on-site technical resources and implementation personnel for project management, database design, installation, and readiness testing

#### Learning Services

Supports client education needs from computer-based training for clinical end-users of Cerner systems to hands-on learning labs for system installers and support specialists

#### Technical Services

Offers technical architecture design, readiness assessments, and overall enterprise system management to ensure system and network organization and performance

#### Benefits Realization Services

Consultants to assist clients with change management, process redesign, operational improvement, and evidence-based care management

## CERNER TECHNOLOGIES

---

#### Computer and Network Equipment

Designer and provider of technology infrastructure for large system integration projects

#### Sublicensed Software

System integration services and provider of operating systems, databases, and other software components



**CERNER CORPORATION**  
**2800 Rockcreek Parkway**  
**Kansas City, MO 64117-2551**  
**(816) 221 1024**  
**(816) 474 1742 (Fax)**  
**<http://www.cerner.com>**

## U N I T E D S T A T E S

### **DETROIT**

28333 Telegraph Road, Suite 500  
Southfield, MI 48034-1903  
(248) 357 1818

### **KANSAS CITY**

2800 Rockcreek Parkway  
Kansas City, MO 64117-2551  
(816) 221-1024

### **DENVER**

3200 Cherry Creek South Drive  
Suite 300  
Denver, CO 80209  
(303) 733-4447

### **WASHINGTON D.C.**

Federal Business Center  
2201 Cooperative way, Suite 301  
Herndon, VA 22071-3024

## I N T E R N A T I O N A L

### **AUSTRALIA**

Cerner Corporation Pty. Ltd.  
Level 10, 52 Alfred Street  
Milsons Point, New South Wales  
2061  
Australia  
+61 2 9925 0988

### **MALAYSIA**

Cerner Malaysia Sdn Bhd  
3rd Floor, Wisma Awal  
171 Jalan Raja Muda Abdul Aziz  
50300 Kuala Lumpur  
Malaysia  
+60 3 291 9139

### **SAUDI ARABIA**

Cerner Arabia Ltd.  
P.O. Box 62433  
Riyadh 11585  
Kingdom of Saudi Arabia  
+966 1 460 0510

### **SINGAPORE**

Cerner Singapore Ltd.  
391A Orchard Road, #12-01  
Ngg Ann City Tower A  
Singapore 238873  
Singapore  
+65 734 3566

### **EUROPE**

Cerner International, Inc  
Waterloo Office Park  
Drève Richelle 161, Bâtiment N  
1410 Waterloo  
Belgium  
+32 2 352 8888

### **CANADA**

Cerner Canada Ltd.  
Cerner Vision Centre  
Phase 1, Tower 2, Level 3  
800 Commissioners Road East  
London, Ontario N6A4G5  
Canada  
(519) 685 8499